https://trial.medpath.com/news/subcutaneous-nivolumab-demonstrates-noninferiority-to-iv-formulation-in-checkmate-67t-trial 2025-10-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-nivolumab-demonstrates-noninferiority-to-iv-formulation-in-checkmate-67t-trial 2025-10-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-secures-first-in-class-pd-l1-protein-degrader-through-qimr-berghofer-partnership 2025-10-07T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-secures-first-in-class-pd-l1-protein-degrader-through-qimr-berghofer-partnership 2025-10-07T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-partners-with-receptor-ai-to-accelerate-ai-driven-neurological-drug-discovery 2025-10-07T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-partners-with-receptor-ai-to-accelerate-ai-driven-neurological-drug-discovery 2025-10-07T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-igc-1c-targets-novel-tau-protein-pathway-in-alzheimer-s-disease 2025-10-07T17:18:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-s-igc-1c-targets-novel-tau-protein-pathway-in-alzheimer-s-disease 2025-10-07T17:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-houston-receives-3-9m-nih-grant-to-develop-first-treatment-for-deadly-cryptosporidium-infections 2025-10-07T17:18:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-houston-receives-3-9m-nih-grant-to-develop-first-treatment-for-deadly-cryptosporidium-infections 2025-10-07T17:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/veris-health-and-ohio-state-university-cancer-center-launch-commercial-digital-cancer-care-platform 2025-10-07T17:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veris-health-and-ohio-state-university-cancer-center-launch-commercial-digital-cancer-care-platform 2025-10-07T17:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-15-new-antidepressants-as-novel-mechanisms-challenge-traditional-depression-treatment 2025-10-07T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-15-new-antidepressants-as-novel-mechanisms-challenge-traditional-depression-treatment 2025-10-07T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-icotrokinra-demonstrates-strong-efficacy-in-phase-2b-ulcerative-colitis-trial 2025-10-07T17:17:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-icotrokinra-demonstrates-strong-efficacy-in-phase-2b-ulcerative-colitis-trial 2025-10-07T17:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/immusoft-achieves-first-ever-safe-re-dosing-of-gene-therapy-patient-with-isp-001-for-mps-i 2025-10-07T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immusoft-achieves-first-ever-safe-re-dosing-of-gene-therapy-patient-with-isp-001-for-mps-i 2025-10-07T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-48-week-solstice-trial-results-for-hepatitis-delta-combination-therapy-at-aasld-2025 2025-10-07T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-48-week-solstice-trial-results-for-hepatitis-delta-combination-therapy-at-aasld-2025 2025-10-07T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/gld-partners-launches-altagenics-to-target-muscle-wasting-diseases-using-advanced-functional-genomics-platform 2025-10-07T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gld-partners-launches-altagenics-to-target-muscle-wasting-diseases-using-advanced-functional-genomics-platform 2025-10-07T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-raises-5-8-million-through-warrant-exercise-to-advance-cancer-drug-pipeline 2025-10-07T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-raises-5-8-million-through-warrant-exercise-to-advance-cancer-drug-pipeline 2025-10-07T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-restart-of-noblestitch-clinical-trial-for-device-free-pfo-closure 2025-10-07T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-restart-of-noblestitch-clinical-trial-for-device-free-pfo-closure 2025-10-07T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-s-mpox-vaccine-shows-superior-immune-response-in-children-aged-2-11-years 2025-10-07T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bavarian-nordic-s-mpox-vaccine-shows-superior-immune-response-in-children-aged-2-11-years 2025-10-07T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-launches-first-in-canada-fast-program-to-accelerate-cancer-drug-access 2025-10-07T17:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-launches-first-in-canada-fast-program-to-accelerate-cancer-drug-access 2025-10-07T17:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/peer-ai-secures-12-1m-to-transform-drug-approval-process-with-specialized-ai-platform 2025-10-07T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peer-ai-secures-12-1m-to-transform-drug-approval-process-with-specialized-ai-platform 2025-10-07T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/ryght-ai-forms-scientific-advisory-board-to-advance-ai-powered-clinical-trial-technology 2025-10-07T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryght-ai-forms-scientific-advisory-board-to-advance-ai-powered-clinical-trial-technology 2025-10-07T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-advances-non-viral-gene-therapy-with-circular-dna-templates-and-tale-base-editor-safety-data 2025-10-07T13:22:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-advances-non-viral-gene-therapy-with-circular-dna-templates-and-tale-base-editor-safety-data 2025-10-07T13:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/who-launches-global-clinical-trials-forum-with-indian-research-institutions-as-key-members 2025-10-07T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-launches-global-clinical-trials-forum-with-indian-research-institutions-as-key-members 2025-10-07T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-s-first-negotiated-drug-prices-launch-january-2026-delivering-1-5-billion-in-patient-savings 2025-10-07T13:18:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-s-first-negotiated-drug-prices-launch-january-2026-delivering-1-5-billion-in-patient-savings 2025-10-07T13:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-unveils-jade201-half-life-extended-anti-baff-receptor-antibody-for-autoimmune-diseases 2025-10-07T13:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jade-biosciences-unveils-jade201-half-life-extended-anti-baff-receptor-antibody-for-autoimmune-diseases 2025-10-07T13:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/nanophoria-secures-98m-series-a-to-advance-novel-heart-failure-treatment 2025-10-07T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanophoria-secures-98m-series-a-to-advance-novel-heart-failure-treatment 2025-10-07T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-expands-us-gene-therapy-manufacturing-with-4-5m-north-carolina-facility-acquisition 2025-10-07T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biomedica-expands-us-gene-therapy-manufacturing-with-4-5m-north-carolina-facility-acquisition 2025-10-07T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/torl-biotherapeutics-raises-96m-series-c-to-advance-claudin-6-targeted-adc-for-platinum-resistant-ovarian-cancer 2025-10-07T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/torl-biotherapeutics-raises-96m-series-c-to-advance-claudin-6-targeted-adc-for-platinum-resistant-ovarian-cancer 2025-10-07T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-appoints-industry-veteran-philippe-monteyne-as-chairman-to-advance-breakthrough-stroke-therapy-biox-101 2025-10-07T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxodes-appoints-industry-veteran-philippe-monteyne-as-chairman-to-advance-breakthrough-stroke-therapy-biox-101 2025-10-07T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/kauvery-hospital-achieves-world-s-first-transcatheter-mitral-valve-replacement-with-novel-technique-for-high-risk-patient 2025-10-07T09:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kauvery-hospital-achieves-world-s-first-transcatheter-mitral-valve-replacement-with-novel-technique-for-high-risk-patient 2025-10-07T09:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/salipro-biotech-secures-two-japanese-patents-for-membrane-protein-technology-platform 2025-10-07T09:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salipro-biotech-secures-two-japanese-patents-for-membrane-protein-technology-platform 2025-10-07T09:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-maat033-microbiome-therapy-passes-second-safety-review-in-pivotal-phase-2b-trial-for-blood-cancer-patients 2025-10-07T09:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-maat033-microbiome-therapy-passes-second-safety-review-in-pivotal-phase-2b-trial-for-blood-cancer-patients 2025-10-07T09:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/beactica-receives-regulatory-support-for-bea-17-development-in-first-swedish-medical-products-agency-advisory-meeting 2025-10-07T09:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beactica-receives-regulatory-support-for-bea-17-development-in-first-swedish-medical-products-agency-advisory-meeting 2025-10-07T09:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/cms-finalizes-ipay-2028-drug-price-negotiation-guidance-expands-program-to-part-b-drugs 2025-10-07T09:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-finalizes-ipay-2028-drug-price-negotiation-guidance-expands-program-to-part-b-drugs 2025-10-07T09:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/molcure-partners-with-boehringer-ingelheim-in-multi-year-ai-driven-antibody-discovery-collaboration 2025-10-07T09:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molcure-partners-with-boehringer-ingelheim-in-multi-year-ai-driven-antibody-discovery-collaboration 2025-10-07T09:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/ribomic-s-umedaptanib-pegol-shows-promising-growth-rate-improvements-in-phase-2-achondroplasia-trial 2025-10-07T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribomic-s-umedaptanib-pegol-shows-promising-growth-rate-improvements-in-phase-2-achondroplasia-trial 2025-10-07T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-pharma-receives-fda-approval-for-tofacitinib-extended-release-tablets 2025-10-07T09:13:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-pharma-receives-fda-approval-for-tofacitinib-extended-release-tablets 2025-10-07T09:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-to-present-expanded-vcn-01-data-and-next-generation-vcn-12-oncolytic-adenovirus-at-major-medical-conferences 2025-10-07T05:15:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theriva-biologics-to-present-expanded-vcn-01-data-and-next-generation-vcn-12-oncolytic-adenovirus-at-major-medical-conferences 2025-10-07T05:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/rovi-rebrands-as-rois-expands-u-s-operations-with-100m-phoenix-manufacturing-facility-acquisition 2025-10-07T01:25:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rovi-rebrands-as-rois-expands-u-s-operations-with-100m-phoenix-manufacturing-facility-acquisition 2025-10-07T01:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-conditional-approval-for-new-world-screwworm-treatment-in-cattle 2025-10-07T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-conditional-approval-for-new-world-screwworm-treatment-in-cattle 2025-10-07T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-therapies-secures-1-085-million-funding-to-advance-stem-cell-therapies-for-disc-disease-and-metabolic-disorders 2025-10-07T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorestorative-therapies-secures-1-085-million-funding-to-advance-stem-cell-therapies-for-disc-disease-and-metabolic-disorders 2025-10-07T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/arcadia-medicine-receives-fda-clearance-for-novel-non-racemic-mdma-compound-am-1002 2025-10-07T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcadia-medicine-receives-fda-clearance-for-novel-non-racemic-mdma-compound-am-1002 2025-10-07T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/clario-partners-with-oxford-to-advance-parkinson-s-disease-research-using-opal-wearable-sensors 2025-10-07T01:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clario-partners-with-oxford-to-advance-parkinson-s-disease-research-using-opal-wearable-sensors 2025-10-07T01:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-secures-500m-debt-facility-to-support-lyme-disease-vaccine-development 2025-10-07T01:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-secures-500m-debt-facility-to-support-lyme-disease-vaccine-development 2025-10-07T01:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/octave-bioscience-receives-grant-to-develop-world-s-first-blood-test-for-multiple-sclerosis-progression 2025-10-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octave-bioscience-receives-grant-to-develop-world-s-first-blood-test-for-multiple-sclerosis-progression 2025-10-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/vicore-pharma-s-buloxibutid-shows-promise-in-ipf-trial-using-innovative-synthetic-control-arms 2025-10-07T01:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicore-pharma-s-buloxibutid-shows-promise-in-ipf-trial-using-innovative-synthetic-control-arms 2025-10-07T01:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-sustained-blood-sugar-control-in-type-2-diabetes-patients-unresponsive-to-glp-1-therapies 2025-10-07T01:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-icovamenib-shows-sustained-blood-sugar-control-in-type-2-diabetes-patients-unresponsive-to-glp-1-therapies 2025-10-07T01:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/cellares-to-build-asia-s-first-automated-car-t-cell-therapy-manufacturing-facility-in-japan 2025-10-07T01:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellares-to-build-asia-s-first-automated-car-t-cell-therapy-manufacturing-facility-in-japan 2025-10-07T01:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/cell-based-influenza-vaccines-show-19-8-superior-effectiveness-over-egg-based-vaccines-in-real-world-study 2025-10-07T01:18:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-based-influenza-vaccines-show-19-8-superior-effectiveness-over-egg-based-vaccines-in-real-world-study 2025-10-07T01:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/form-bio-and-cure-rare-disease-partner-to-accelerate-gene-therapy-development-for-duchenne-muscular-dystrophy 2025-10-07T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/form-bio-and-cure-rare-disease-partner-to-accelerate-gene-therapy-development-for-duchenne-muscular-dystrophy 2025-10-07T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-sustained-diabetes-benefits-nine-months-after-treatment-ends 2025-10-07T01:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-icovamenib-shows-sustained-diabetes-benefits-nine-months-after-treatment-ends 2025-10-07T01:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-reports-sustained-one-year-functional-improvements-with-zeleciment-basivarsen-in-myotonic-dystrophy-type-1 2025-10-07T01:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-reports-sustained-one-year-functional-improvements-with-zeleciment-basivarsen-in-myotonic-dystrophy-type-1 2025-10-07T01:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/moffitt-cancer-center-receives-22-4m-grant-to-pioneer-clinical-trials-for-leptomeningeal-disease 2025-10-06T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moffitt-cancer-center-receives-22-4m-grant-to-pioneer-clinical-trials-for-leptomeningeal-disease 2025-10-06T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/algen-biotechnologies-partners-with-astrazeneca-in-555m-ai-driven-drug-discovery-deal-for-immunology-targets 2025-10-06T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algen-biotechnologies-partners-with-astrazeneca-in-555m-ai-driven-drug-discovery-deal-for-immunology-targets 2025-10-06T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/placental-stem-cell-hydrogel-shows-promise-in-phase-ii-trial-for-radiation-induced-skin-injuries 2025-10-06T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/placental-stem-cell-hydrogel-shows-promise-in-phase-ii-trial-for-radiation-induced-skin-injuries 2025-10-06T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-announce-pivotal-phase-3-trial-for-pridopidine-in-als-following-encouraging-phase-2-results 2025-10-06T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prilenia-and-ferrer-announce-pivotal-phase-3-trial-for-pridopidine-in-als-following-encouraging-phase-2-results 2025-10-06T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-receives-fda-clearance-for-phase-2a-mosaic-trial-testing-dual-target-mash-therapy 2025-10-06T17:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eccogene-receives-fda-clearance-for-phase-2a-mosaic-trial-testing-dual-target-mash-therapy 2025-10-06T17:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/revbio-secures-2-2-million-nih-grant-to-advance-tetranite-bone-adhesive-for-vertebral-fracture-treatment 2025-10-06T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revbio-secures-2-2-million-nih-grant-to-advance-tetranite-bone-adhesive-for-vertebral-fracture-treatment 2025-10-06T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/topical-bimiralisib-achieves-92-clearance-rate-in-phase-2-actinic-keratosis-trial 2025-10-06T17:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-bimiralisib-achieves-92-clearance-rate-in-phase-2-actinic-keratosis-trial 2025-10-06T17:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-ta-ert-receives-fda-breakthrough-therapy-designation-for-ultra-rare-sanfilippo-syndrome-type-b 2025-10-06T17:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-ta-ert-receives-fda-breakthrough-therapy-designation-for-ultra-rare-sanfilippo-syndrome-type-b 2025-10-06T17:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ucla-s-heart-regeneration-drug-ad-np1-for-clinical-trials 2025-10-06T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ucla-s-heart-regeneration-drug-ad-np1-for-clinical-trials 2025-10-06T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-botox-shows-promise-for-essential-tremor-in-phase-2-elate-trial 2025-10-06T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-botox-shows-promise-for-essential-tremor-in-phase-2-elate-trial 2025-10-06T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/marker-therapeutics-initiates-first-off-the-shelf-t-cell-therapy-trial-with-promising-early-safety-data 2025-10-06T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marker-therapeutics-initiates-first-off-the-shelf-t-cell-therapy-trial-with-promising-early-safety-data 2025-10-06T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/historic-malaria-trial-enrolls-first-pregnant-woman-in-mali-addressing-critical-treatment-gap 2025-10-06T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/historic-malaria-trial-enrolls-first-pregnant-woman-in-mali-addressing-critical-treatment-gap 2025-10-06T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-s-cb1-inhibitor-nimacimab-fails-monotherapy-trial-but-shows-promise-in-combination-with-semaglutide 2025-10-06T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skye-bioscience-s-cb1-inhibitor-nimacimab-fails-monotherapy-trial-but-shows-promise-in-combination-with-semaglutide 2025-10-06T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-launches-direct-to-patient-program-for-cholesterol-drug-repatha-at-60-discount 2025-10-06T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-launches-direct-to-patient-program-for-cholesterol-drug-repatha-at-60-discount 2025-10-06T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/novel-body-composition-model-predicts-gastric-cancer-response-to-pd-1-immunotherapy 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-body-composition-model-predicts-gastric-cancer-response-to-pd-1-immunotherapy 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-cardiovascular-medicine-emerges-as-new-paradigm-to-address-disease-heterogeneity-and-drug-development-challenges 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-cardiovascular-medicine-emerges-as-new-paradigm-to-address-disease-heterogeneity-and-drug-development-challenges 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-reveals-emicizumab-cost-effectiveness-varies-by-patient-population-and-comparator-in-hemophilia-a-treatment 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-reveals-emicizumab-cost-effectiveness-varies-by-patient-population-and-comparator-in-hemophilia-a-treatment 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-and-celltrion-expand-biosimilar-access-across-mena-through-exclusive-partnership 2025-10-06T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-and-celltrion-expand-biosimilar-access-across-mena-through-exclusive-partnership 2025-10-06T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/irish-court-invalidates-bayer-s-rivaroxaban-dosing-patent-in-eur3-5-billion-xarelto-challenge 2025-10-06T13:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irish-court-invalidates-bayer-s-rivaroxaban-dosing-patent-in-eur3-5-billion-xarelto-challenge 2025-10-06T13:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/merck-expands-tulisokibart-clinical-program-with-three-new-phase-2b-trials-across-immune-mediated-inflammatory-diseases 2025-10-06T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-expands-tulisokibart-clinical-program-with-three-new-phase-2b-trials-across-immune-mediated-inflammatory-diseases 2025-10-06T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-appoints-ian-smith-as-ceo-as-phase-3-trial-for-dravet-syndrome-treatment-advances 2025-10-06T13:16:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-appoints-ian-smith-as-ceo-as-phase-3-trial-for-dravet-syndrome-treatment-advances 2025-10-06T13:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/owlstone-medical-secures-49-1m-arpa-h-award-to-develop-revolutionary-at-home-multi-cancer-detection-tests 2025-10-06T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/owlstone-medical-secures-49-1m-arpa-h-award-to-develop-revolutionary-at-home-multi-cancer-detection-tests 2025-10-06T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-s-cxcr4-targeted-radiopharmaceuticals-show-promise-in-primary-aldosteronism-and-bladder-cancer 2025-10-06T13:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pentixapharm-s-cxcr4-targeted-radiopharmaceuticals-show-promise-in-primary-aldosteronism-and-bladder-cancer 2025-10-06T13:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-mifepristone-as-takeda-discontinues-cell-therapy-research-programs 2025-10-06T13:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-mifepristone-as-takeda-discontinues-cell-therapy-research-programs 2025-10-06T13:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/csl-behring-secures-canadian-reimbursement-agreement-for-first-gene-therapy-for-hemophilia-b 2025-10-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-behring-secures-canadian-reimbursement-agreement-for-first-gene-therapy-for-hemophilia-b 2025-10-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-secures-95-million-series-a-to-advance-revolutionary-cancer-platform-targeting-glioblastoma 2025-10-06T09:16:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trogenix-secures-95-million-series-a-to-advance-revolutionary-cancer-platform-targeting-glioblastoma 2025-10-06T09:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/harness-therapeutics-launches-misba-duo-platform-for-dual-target-neurodegenerative-disease-treatment 2025-10-06T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harness-therapeutics-launches-misba-duo-platform-for-dual-target-neurodegenerative-disease-treatment 2025-10-06T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/nigerian-government-backs-homegrown-brain-cancer-treatment-research-with-multi-institute-support 2025-10-06T09:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigerian-government-backs-homegrown-brain-cancer-treatment-research-with-multi-institute-support 2025-10-06T09:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-ce-mark-for-first-ai-based-kidney-risk-assessment-tool 2025-10-06T09:14:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-ce-mark-for-first-ai-based-kidney-risk-assessment-tool 2025-10-06T09:14:07+00:00 hourly 0.9 https://trial.medpath.com/news/ignota-labs-acquires-kronos-bio-s-failed-clinical-pipeline-to-revive-shelved-cancer-and-autoimmune-drugs 2025-10-06T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ignota-labs-acquires-kronos-bio-s-failed-clinical-pipeline-to-revive-shelved-cancer-and-autoimmune-drugs 2025-10-06T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-generic-liraglutide-injection-in-us-market-despite-fda-manufacturing-compliance-issues 2025-10-06T09:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-launches-generic-liraglutide-injection-in-us-market-despite-fda-manufacturing-compliance-issues 2025-10-06T09:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/d-c-circuit-court-upholds-skinny-label-practice-for-generic-drug-manufacturers 2025-10-06T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-c-circuit-court-upholds-skinny-label-practice-for-generic-drug-manufacturers 2025-10-06T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-therapeutics-to-present-ct0596-allogeneic-car-t-data-at-ash-2025 2025-10-06T05:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-therapeutics-to-present-ct0596-allogeneic-car-t-data-at-ash-2025 2025-10-06T05:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/risvodetinib-shows-first-ever-reduction-in-alpha-synuclein-pathology-in-phase-2-parkinson-s-disease-trial 2025-10-06T05:19:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risvodetinib-shows-first-ever-reduction-in-alpha-synuclein-pathology-in-phase-2-parkinson-s-disease-trial 2025-10-06T05:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/indian-immunologicals-receives-regulatory-approval-for-phase-i-trial-of-kyasanur-forest-disease-vaccine 2025-10-06T05:18:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-immunologicals-receives-regulatory-approval-for-phase-i-trial-of-kyasanur-forest-disease-vaccine 2025-10-06T05:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/iksuda-therapeutics-to-present-phase-1-data-for-her2-targeting-adc-iks014-at-esmo-congress 2025-10-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iksuda-therapeutics-to-present-phase-1-data-for-her2-targeting-adc-iks014-at-esmo-congress 2025-10-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-clinical-data-show-vatiquinone-and-omaveloxolone-slow-friedreich-s-ataxia-progression 2025-10-05T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-clinical-data-show-vatiquinone-and-omaveloxolone-slow-friedreich-s-ataxia-progression 2025-10-05T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/guard-therapeutics-rmc-035-fails-phase-2b-pointer-trial-despite-earlier-positive-results 2025-10-05T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guard-therapeutics-rmc-035-fails-phase-2b-pointer-trial-despite-earlier-positive-results 2025-10-05T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/qlife-holding-extends-letter-of-intent-with-hipro-biotechnology-for-reverse-takeover-through-december-2025 2025-10-05T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlife-holding-extends-letter-of-intent-with-hipro-biotechnology-for-reverse-takeover-through-december-2025 2025-10-05T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-advances-70m-turkish-drug-contract-with-health-canada-review-of-generic-acetaminophen 2025-10-05T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-advances-70m-turkish-drug-contract-with-health-canada-review-of-generic-acetaminophen 2025-10-05T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/needle-free-vaccine-delivery-through-skin-stretching-shows-superior-immune-response-in-preclinical-study 2025-10-05T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/needle-free-vaccine-delivery-through-skin-stretching-shows-superior-immune-response-in-preclinical-study 2025-10-05T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-reports-positive-phase-3-metis-trial-results-for-brain-metastases-from-lung-cancer 2025-10-05T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-reports-positive-phase-3-metis-trial-results-for-brain-metastases-from-lung-cancer 2025-10-05T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-pdufa-viii-negotiations-with-industry-leaders-emphasizing-america-first-approach 2025-10-05T01:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-initiates-pdufa-viii-negotiations-with-industry-leaders-emphasizing-america-first-approach 2025-10-05T01:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/fdc-limited-receives-fda-approval-for-generic-pilocarpine-hcl-ophthalmic-solution 2025-10-05T01:37:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fdc-limited-receives-fda-approval-for-generic-pilocarpine-hcl-ophthalmic-solution 2025-10-05T01:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-accelerates-pfizer-biontech-covid-19-vaccine-review-following-pressure-from-eu-member-states 2025-10-05T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-accelerates-pfizer-biontech-covid-19-vaccine-review-following-pressure-from-eu-member-states 2025-10-05T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-stock-shows-mixed-valuation-signals-following-recent-fda-approval-and-market-recovery 2025-10-05T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyowa-kirin-stock-shows-mixed-valuation-signals-following-recent-fda-approval-and-market-recovery 2025-10-05T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-therapeutics-stock-surges-13-1-following-patent-settlement-victory-with-dr-reddy-s 2025-10-04T21:40:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-therapeutics-stock-surges-13-1-following-patent-settlement-victory-with-dr-reddy-s 2025-10-04T21:40:16+00:00 hourly 0.9 https://trial.medpath.com/news/vasopressin-shows-promise-as-alternative-to-epinephrine-in-neonatal-resuscitation-study 2025-10-04T21:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vasopressin-shows-promise-as-alternative-to-epinephrine-in-neonatal-resuscitation-study 2025-10-04T21:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-major-gaps-in-phase-iii-cancer-trial-design-and-patient-centered-outcomes 2025-10-04T21:39:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-major-gaps-in-phase-iii-cancer-trial-design-and-patient-centered-outcomes 2025-10-04T21:39:29+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-acoramidis-demonstrates-sustained-cardiovascular-benefits-in-phase-3-attr-cm-trial 2025-10-04T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-acoramidis-demonstrates-sustained-cardiovascular-benefits-in-phase-3-attr-cm-trial 2025-10-04T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-reports-positive-phase-1-results-for-ov329-in-drug-resistant-epilepsy 2025-10-04T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-reports-positive-phase-1-results-for-ov329-in-drug-resistant-epilepsy 2025-10-04T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-launches-multi-state-drug-manufacturing-inspections-following-fatal-cough-syrup-contamination 2025-10-04T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-launches-multi-state-drug-manufacturing-inspections-following-fatal-cough-syrup-contamination 2025-10-04T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-advances-otx-tki-phase-3-trials-for-wet-amd-with-novel-9-month-sustained-release-platform 2025-10-04T17:12:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-advances-otx-tki-phase-3-trials-for-wet-amd-with-novel-9-month-sustained-release-platform 2025-10-04T17:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-sets-first-in-nation-price-ceiling-on-amgen-s-enbrel-limiting-annual-costs-to-31200 2025-10-04T13:14:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-sets-first-in-nation-price-ceiling-on-amgen-s-enbrel-limiting-annual-costs-to-31200 2025-10-04T13:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-becomes-mandatory-component-of-drug-development-and-post-market-surveillance 2025-10-04T13:14:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-becomes-mandatory-component-of-drug-development-and-post-market-surveillance 2025-10-04T13:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/bajaj-healthcare-receives-cdsco-approval-for-phase-iii-suvorexant-trials-in-india 2025-10-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bajaj-healthcare-receives-cdsco-approval-for-phase-iii-suvorexant-trials-in-india 2025-10-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-and-clywedog-therapeutics-announce-merger-to-advance-diabetes-and-celiac-disease-therapies 2025-10-04T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barinthus-bio-and-clywedog-therapeutics-announce-merger-to-advance-diabetes-and-celiac-disease-therapies 2025-10-04T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/novithera-initiates-preclinical-studies-for-novel-monoclonal-antibody-targeting-psoriasis 2025-10-04T01:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novithera-initiates-preclinical-studies-for-novel-monoclonal-antibody-targeting-psoriasis 2025-10-04T01:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/ctmc-partners-with-einstein-hospital-to-launch-global-cell-therapy-network-alliance 2025-10-04T01:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctmc-partners-with-einstein-hospital-to-launch-global-cell-therapy-network-alliance 2025-10-04T01:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-fast-track-review-program-for-u-s-made-generic-drugs-to-strengthen-supply-chain-resilience 2025-10-04T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-fast-track-review-program-for-u-s-made-generic-drugs-to-strengthen-supply-chain-resilience 2025-10-04T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/titan-pharmaceuticals-completes-merger-with-black-titan-corporation-creating-new-nasdaq-listed-entity 2025-10-03T22:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/titan-pharmaceuticals-completes-merger-with-black-titan-corporation-creating-new-nasdaq-listed-entity 2025-10-03T22:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/aulos-bioscience-to-present-updated-phase-2-data-for-ai-designed-imneskibart-in-checkpoint-inhibitor-refractory-cancers-at-sitc-2025 2025-10-03T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aulos-bioscience-to-present-updated-phase-2-data-for-ai-designed-imneskibart-in-checkpoint-inhibitor-refractory-cancers-at-sitc-2025 2025-10-03T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-oncology-to-present-chs-114-anti-ccr8-antibody-data-showing-selective-treg-depletion-at-sitc-2025 2025-10-03T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-oncology-to-present-chs-114-anti-ccr8-antibody-data-showing-selective-treg-depletion-at-sitc-2025 2025-10-03T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/ansa-biotechnologies-raises-54-4-million-series-b-to-revolutionize-dna-synthesis-with-enzymatic-platform 2025-10-03T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ansa-biotechnologies-raises-54-4-million-series-b-to-revolutionize-dna-synthesis-with-enzymatic-platform 2025-10-03T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-regulators-face-mounting-pressure-to-crack-down-on-compounded-glp-1-weight-loss-drugs 2025-10-03T21:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-regulators-face-mounting-pressure-to-crack-down-on-compounded-glp-1-weight-loss-drugs 2025-10-03T21:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-unveils-dcaf2-as-novel-e3-ligase-for-targeted-protein-degradation-in-cancer-treatment 2025-10-03T21:13:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontier-medicines-unveils-dcaf2-as-novel-e3-ligase-for-targeted-protein-degradation-in-cancer-treatment 2025-10-03T21:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/senator-gallego-demands-transparency-on-pfizer-trump-administration-drug-pricing-agreement 2025-10-03T21:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senator-gallego-demands-transparency-on-pfizer-trump-administration-drug-pricing-agreement 2025-10-03T21:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-pharmaceutical-exits-cell-therapy-to-focus-on-near-term-commercial-programs 2025-10-03T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-pharmaceutical-exits-cell-therapy-to-focus-on-near-term-commercial-programs 2025-10-03T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/enara-bio-unveils-darkfox-dark-antigen-for-solid-tumor-immunotherapy-at-sitc-2025 2025-10-03T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enara-bio-unveils-darkfox-dark-antigen-for-solid-tumor-immunotherapy-at-sitc-2025 2025-10-03T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/curonix-freedom-pns-system-demonstrates-69-response-rate-in-first-fda-approved-randomized-trial-for-chronic-craniofacial-pain 2025-10-03T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curonix-freedom-pns-system-demonstrates-69-response-rate-in-first-fda-approved-randomized-trial-for-chronic-craniofacial-pain 2025-10-03T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/kihealth-secures-5m-to-commercialize-first-of-its-kind-beta-cell-apoptosis-diagnostic-for-early-diabetes-detection 2025-10-03T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kihealth-secures-5m-to-commercialize-first-of-its-kind-beta-cell-apoptosis-diagnostic-for-early-diabetes-detection 2025-10-03T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-partners-with-sanofi-to-develop-population-scale-type-1-diabetes-screening-test 2025-10-03T17:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-partners-with-sanofi-to-develop-population-scale-type-1-diabetes-screening-test 2025-10-03T17:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-successfully-transplant-first-universal-donor-kidney-after-blood-type-conversion 2025-10-03T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-successfully-transplant-first-universal-donor-kidney-after-blood-type-conversion 2025-10-03T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/kernal-bio-joins-lilly-gateway-labs-to-advance-ai-driven-in-vivo-cell-therapies 2025-10-03T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kernal-bio-joins-lilly-gateway-labs-to-advance-ai-driven-in-vivo-cell-therapies 2025-10-03T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/radiant-biotherapeutics-to-present-novel-multabody-technology-for-cancer-immunotherapy-at-sitc-2025 2025-10-03T17:22:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiant-biotherapeutics-to-present-novel-multabody-technology-for-cancer-immunotherapy-at-sitc-2025 2025-10-03T17:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-to-present-phase-1-data-for-bi-1910-tnfr2-agonist-at-sitc-despite-pausing-development 2025-10-03T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-to-present-phase-1-data-for-bi-1910-tnfr2-agonist-at-sitc-despite-pausing-development 2025-10-03T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-secures-175m-pipe-financing-to-advance-cns-drug-pipeline-through-2028 2025-10-03T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-secures-175m-pipe-financing-to-advance-cns-drug-pipeline-through-2028 2025-10-03T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-to-present-phase-3-data-on-continuous-levodopa-infusion-nd0612-for-parkinson-s-disease 2025-10-03T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-to-present-phase-3-data-on-continuous-levodopa-infusion-nd0612-for-parkinson-s-disease 2025-10-03T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-advances-srp-1003-sirna-therapy-for-myotonic-dystrophy-type-1-with-positive-safety-review 2025-10-03T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-advances-srp-1003-sirna-therapy-for-myotonic-dystrophy-type-1-with-positive-safety-review 2025-10-03T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-receives-fda-fast-track-designation-for-alto-101-schizophrenia-cognitive-impairment-treatment 2025-10-03T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alto-neuroscience-receives-fda-fast-track-designation-for-alto-101-schizophrenia-cognitive-impairment-treatment 2025-10-03T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-peptide-drug-nvg-291-shows-promise-in-phase-2-trial-for-spinal-cord-injury-recovery 2025-10-03T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-peptide-drug-nvg-291-shows-promise-in-phase-2-trial-for-spinal-cord-injury-recovery 2025-10-03T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-withdraws-fda-application-for-fanconi-anemia-gene-therapy-rp-l102 2025-10-03T13:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-withdraws-fda-application-for-fanconi-anemia-gene-therapy-rp-l102 2025-10-03T13:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-discovery-of-enterololin-offers-new-hope-for-ibd-treatment 2025-10-03T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-guided-discovery-of-enterololin-offers-new-hope-for-ibd-treatment 2025-10-03T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-repatha-demonstrates-long-term-cardiovascular-benefits-in-phase-iii-vesalius-cv-trial 2025-10-03T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-repatha-demonstrates-long-term-cardiovascular-benefits-in-phase-iii-vesalius-cv-trial 2025-10-03T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-eight-science-priorities-for-2026-generic-drug-program-emphasizing-ai-integration-and-complex-product-development 2025-10-03T13:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-unveils-eight-science-priorities-for-2026-generic-drug-program-emphasizing-ai-integration-and-complex-product-development 2025-10-03T13:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-ov329-shows-53-gaba-inhibition-in-phase-1-trial-for-drug-resistant-epilepsy 2025-10-03T13:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-ov329-shows-53-gaba-inhibition-in-phase-1-trial-for-drug-resistant-epilepsy 2025-10-03T13:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/medhub-ai-secures-national-reimbursement-approval-in-japan-for-ai-powered-coronary-assessment-system 2025-10-03T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medhub-ai-secures-national-reimbursement-approval-in-japan-for-ai-powered-coronary-assessment-system 2025-10-03T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-elephant-herpesvirus-vaccine-shows-promise-in-breakthrough-safety-trial 2025-10-03T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-elephant-herpesvirus-vaccine-shows-promise-in-breakthrough-safety-trial 2025-10-03T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/heriot-watt-university-secures-ps475000-for-revolutionary-vibroacoustic-sensor-to-transform-eczema-diagnosis-and-treatment 2025-10-03T09:15:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heriot-watt-university-secures-ps475000-for-revolutionary-vibroacoustic-sensor-to-transform-eczema-diagnosis-and-treatment 2025-10-03T09:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/aberdeen-royal-infirmary-launches-car-t-cell-therapy-program-first-patient-achieves-remission 2025-10-03T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aberdeen-royal-infirmary-launches-car-t-cell-therapy-program-first-patient-achieves-remission 2025-10-03T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-rs-4200-crore-prip-scheme-to-boost-pharmaceutical-and-medtech-r-d-innovation 2025-10-03T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-rs-4200-crore-prip-scheme-to-boost-pharmaceutical-and-medtech-r-d-innovation 2025-10-03T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-outlines-2026-medical-device-regulatory-guidance-priorities-emphasizes-real-world-evidence-and-ai-software-oversight 2025-10-03T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-outlines-2026-medical-device-regulatory-guidance-priorities-emphasizes-real-world-evidence-and-ai-software-oversight 2025-10-03T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/ss-innovations-pivots-to-510-k-pathway-for-ssi-mantra-surgical-robot-fda-approval 2025-10-03T05:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ss-innovations-pivots-to-510-k-pathway-for-ssi-mantra-surgical-robot-fda-approval 2025-10-03T05:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/monash-university-establishes-boston-hub-to-accelerate-global-drug-discovery-partnerships 2025-10-03T05:16:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monash-university-establishes-boston-hub-to-accelerate-global-drug-discovery-partnerships 2025-10-03T05:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-strengthens-leadership-with-quality-operations-expert-to-advance-adc-platform 2025-10-03T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-strengthens-leadership-with-quality-operations-expert-to-advance-adc-platform 2025-10-03T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-agamree-as-first-treatment-for-duchenne-muscular-dystrophy-in-canada 2025-10-03T01:22:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-agamree-as-first-treatment-for-duchenne-muscular-dystrophy-in-canada 2025-10-03T01:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/quanthealth-secures-strategic-investment-from-sanofi-ventures-to-advance-ai-driven-clinical-trial-simulation 2025-10-03T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanthealth-secures-strategic-investment-from-sanofi-ventures-to-advance-ai-driven-clinical-trial-simulation 2025-10-03T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-to-present-aav-gene-therapy-advances-at-esgct-2025-meeting 2025-10-03T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-to-present-aav-gene-therapy-advances-at-esgct-2025-meeting 2025-10-03T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/rockcliffe-labs-secures-75-million-financing-for-late-stage-sepsis-biomarker-program 2025-10-03T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rockcliffe-labs-secures-75-million-financing-for-late-stage-sepsis-biomarker-program 2025-10-03T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/vivex-biologics-initiates-pivotal-trial-for-via-disc-np-in-degenerative-disc-disease 2025-10-03T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivex-biologics-initiates-pivotal-trial-for-via-disc-np-in-degenerative-disc-disease 2025-10-03T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-generic-mifepristone-from-evita-solutions-drawing-congressional-criticism 2025-10-03T01:13:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-generic-mifepristone-from-evita-solutions-drawing-congressional-criticism 2025-10-03T01:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-genentech-s-tecentriq-plus-lurbinectedin-as-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-10-03T01:12:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-genentech-s-tecentriq-plus-lurbinectedin-as-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-10-03T01:12:54+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-partners-with-astrazeneca-bioventurehub-for-collaborative-r-d-innovation 2025-10-02T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-partners-with-astrazeneca-bioventurehub-for-collaborative-r-d-innovation 2025-10-02T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-generic-mifepristone-despite-trump-administration-safety-review 2025-10-02T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-second-generic-mifepristone-despite-trump-administration-safety-review 2025-10-02T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/medsir-and-ataraxis-ai-launch-strategic-collaboration-to-integrate-ai-platform-in-breast-cancer-clinical-trials 2025-10-02T21:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medsir-and-ataraxis-ai-launch-strategic-collaboration-to-integrate-ai-platform-in-breast-cancer-clinical-trials 2025-10-02T21:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-obinutuzumab-awaits-fda-decision-as-lupus-market-analysis-reveals-launch-success-factors 2025-10-02T17:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-obinutuzumab-awaits-fda-decision-as-lupus-market-analysis-reveals-launch-success-factors 2025-10-02T17:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/neuraptive-therapeutics-initiates-phase-3-trial-for-ntx-001-in-traumatic-peripheral-nerve-injuries 2025-10-02T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraptive-therapeutics-initiates-phase-3-trial-for-ntx-001-in-traumatic-peripheral-nerve-injuries 2025-10-02T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/hologic-receives-fda-clearance-for-automated-gi-bacterial-pathogen-detection-assays 2025-10-02T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hologic-receives-fda-clearance-for-automated-gi-bacterial-pathogen-detection-assays 2025-10-02T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/igyxos-biotherapeutics-secures-eur5-7-million-french-government-grant-to-advance-first-in-class-infertility-treatment 2025-10-02T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igyxos-biotherapeutics-secures-eur5-7-million-french-government-grant-to-advance-first-in-class-infertility-treatment 2025-10-02T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/sotio-biotech-appoints-amy-jensen-smith-as-cso-and-ulrich-moebius-as-cdo-to-advance-adc-pipeline 2025-10-02T17:28:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sotio-biotech-appoints-amy-jensen-smith-as-cso-and-ulrich-moebius-as-cdo-to-advance-adc-pipeline 2025-10-02T17:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/cirrus-therapeutics-secures-11m-to-advance-gene-therapy-targeting-age-related-cause-of-dry-amd 2025-10-02T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirrus-therapeutics-secures-11m-to-advance-gene-therapy-targeting-age-related-cause-of-dry-amd 2025-10-02T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/incendia-s-prth-101-shows-promise-in-rare-thymic-cancers-with-7-9-month-median-pfs 2025-10-02T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incendia-s-prth-101-shows-promise-in-rare-thymic-cancers-with-7-9-month-median-pfs 2025-10-02T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/restart-trial-launches-to-test-novel-hiv-treatment-targeting-toxic-viral-protein-gp120 2025-10-02T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restart-trial-launches-to-test-novel-hiv-treatment-targeting-toxic-viral-protein-gp120 2025-10-02T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-publishes-promising-preclinical-data-on-donor-derived-gd-t-cell-therapy-for-acute-myeloid-leukemia 2025-10-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-publishes-promising-preclinical-data-on-donor-derived-gd-t-cell-therapy-for-acute-myeloid-leukemia 2025-10-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/anavex-reports-positive-phase-2-results-for-anavex-r-3-71-in-schizophrenia-and-successful-once-daily-formulation-development 2025-10-02T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anavex-reports-positive-phase-2-results-for-anavex-r-3-71-in-schizophrenia-and-successful-once-daily-formulation-development 2025-10-02T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/london-health-sciences-centre-launches-phase-ii-trial-of-internal-radiation-therapy-for-kidney-cancer 2025-10-02T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/london-health-sciences-centre-launches-phase-ii-trial-of-internal-radiation-therapy-for-kidney-cancer 2025-10-02T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/bial-s-bia-28-6156-reaches-key-milestone-in-phase-2-trial-for-gba-associated-parkinson-s-disease 2025-10-02T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bial-s-bia-28-6156-reaches-key-milestone-in-phase-2-trial-for-gba-associated-parkinson-s-disease 2025-10-02T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/draig-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-ampa-receptor-modulator-dt-101-in-major-depressive-disorder 2025-10-02T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/draig-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-ampa-receptor-modulator-dt-101-in-major-depressive-disorder 2025-10-02T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-presents-5-year-survival-data-for-lenvatinib-plus-pembrolizumab-in-endometrial-cancer-at-esmo-2025 2025-10-02T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-presents-5-year-survival-data-for-lenvatinib-plus-pembrolizumab-in-endometrial-cancer-at-esmo-2025 2025-10-02T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/sitryx-receives-fda-clearance-for-first-in-class-pkm2-modulator-syx-5219-in-atopic-dermatitis 2025-10-02T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sitryx-receives-fda-clearance-for-first-in-class-pkm2-modulator-syx-5219-in-atopic-dermatitis 2025-10-02T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/wisconsin-biotech-secures-1-8m-nih-grant-to-advance-ipsc-based-diabetes-cure 2025-10-02T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wisconsin-biotech-secures-1-8m-nih-grant-to-advance-ipsc-based-diabetes-cure 2025-10-02T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/start-and-minerva-imaging-expand-partnership-to-create-integrated-radiopharmaceutical-development-platform 2025-10-02T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-and-minerva-imaging-expand-partnership-to-create-integrated-radiopharmaceutical-development-platform 2025-10-02T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/am-pharma-completes-phase-2-enrollment-for-ilofotase-alfa-in-cardiac-surgery-associated-kidney-injury-prevention 2025-10-02T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/am-pharma-completes-phase-2-enrollment-for-ilofotase-alfa-in-cardiac-surgery-associated-kidney-injury-prevention 2025-10-02T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-nacuity-s-npi-001-for-retinitis-pigmentosa-treatment 2025-10-02T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-nacuity-s-npi-001-for-retinitis-pigmentosa-treatment 2025-10-02T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/calico-s-abbv-cls-628-receives-fda-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease 2025-10-02T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calico-s-abbv-cls-628-receives-fda-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease 2025-10-02T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-repatha-becomes-first-pcsk9-inhibitor-to-demonstrate-primary-prevention-of-cardiovascular-events-in-landmark-12000-patient-trial 2025-10-02T17:16:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-repatha-becomes-first-pcsk9-inhibitor-to-demonstrate-primary-prevention-of-cardiovascular-events-in-landmark-12000-patient-trial 2025-10-02T17:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-s-hsv-gene-therapy-shows-88-reduction-in-urinary-incontinence-episodes-in-phase-ib-iia-trial 2025-10-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eg-427-s-hsv-gene-therapy-shows-88-reduction-in-urinary-incontinence-episodes-in-phase-ib-iia-trial 2025-10-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/vanqua-bio-s-vq-101-achieves-over-70-gcase-activation-in-phase-1b-trial-for-gba-parkinson-s-disease 2025-10-02T13:19:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanqua-bio-s-vq-101-achieves-over-70-gcase-activation-in-phase-1b-trial-for-gba-parkinson-s-disease 2025-10-02T13:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/cartography-biosciences-raises-67m-series-b-to-advance-novel-t-cell-engager-for-colorectal-cancer 2025-10-02T13:18:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartography-biosciences-raises-67m-series-b-to-advance-novel-t-cell-engager-for-colorectal-cancer 2025-10-02T13:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-secures-50-million-series-b-funding-to-advance-immuno-oncology-pipeline 2025-10-02T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-secures-50-million-series-b-funding-to-advance-immuno-oncology-pipeline 2025-10-02T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/asabys-partners-integrates-aliath-bioventures-in-eur468m-strategic-consolidation-to-build-eur1b-life-sciences-platform 2025-10-02T13:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asabys-partners-integrates-aliath-bioventures-in-eur468m-strategic-consolidation-to-build-eur1b-life-sciences-platform 2025-10-02T13:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/edinburgh-researchers-develop-anti-cancer-drug-potentially-500-times-more-effective-than-current-treatments 2025-10-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edinburgh-researchers-develop-anti-cancer-drug-potentially-500-times-more-effective-than-current-treatments 2025-10-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/who-reports-alarming-decline-in-antibacterial-pipeline-as-drug-resistance-crisis-deepens 2025-10-02T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-reports-alarming-decline-in-antibacterial-pipeline-as-drug-resistance-crisis-deepens 2025-10-02T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/india-approves-1500-crore-biomedical-research-career-programme-phase-iii-to-train-2000-scientists-by-2031 2025-10-02T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-approves-1500-crore-biomedical-research-career-programme-phase-iii-to-train-2000-scientists-by-2031 2025-10-02T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/msn-labs-receives-regulatory-approval-for-phase-iii-trial-of-vibegron-75-mg-in-overactive-bladder 2025-10-02T13:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msn-labs-receives-regulatory-approval-for-phase-iii-trial-of-vibegron-75-mg-in-overactive-bladder 2025-10-02T13:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-advances-innovative-phase-3-trial-design-for-amlenetug-in-multiple-system-atrophy 2025-10-02T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-advances-innovative-phase-3-trial-design-for-amlenetug-in-multiple-system-atrophy 2025-10-02T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/race-oncology-discovers-novel-mechanism-for-cancer-drug-targeting-previously-undruggable-myc-pathway 2025-10-02T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/race-oncology-discovers-novel-mechanism-for-cancer-drug-targeting-previously-undruggable-myc-pathway 2025-10-02T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/arovella-s-cldn18-2-car-inkt-therapy-shows-potent-activity-against-pancreatic-cancer-cells 2025-10-02T05:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arovella-s-cldn18-2-car-inkt-therapy-shows-potent-activity-against-pancreatic-cancer-cells 2025-10-02T05:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-secures-us-patent-protection-for-copper-based-fap-targeting-radiotheranostics-platform 2025-10-02T02:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclidium-secures-us-patent-protection-for-copper-based-fap-targeting-radiotheranostics-platform 2025-10-02T02:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/northern-ireland-children-with-duchenne-muscular-dystrophy-gain-access-to-givinostat-through-early-access-programme 2025-10-02T01:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northern-ireland-children-with-duchenne-muscular-dystrophy-gain-access-to-givinostat-through-early-access-programme 2025-10-02T01:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/pop-biotechnologies-secures-2-46m-nih-grant-for-novel-dual-target-alzheimer-s-immunotherapy 2025-10-02T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pop-biotechnologies-secures-2-46m-nih-grant-for-novel-dual-target-alzheimer-s-immunotherapy 2025-10-02T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-scientists-develop-precision-gene-therapy-for-kaposi-s-sarcoma-using-viral-trojan-horse-strategy 2025-10-02T01:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-scientists-develop-precision-gene-therapy-for-kaposi-s-sarcoma-using-viral-trojan-horse-strategy 2025-10-02T01:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-semaglutide-fails-in-alzheimer-s-trials-boosting-biogen-s-leqembi-prospects 2025-10-02T01:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-semaglutide-fails-in-alzheimer-s-trials-boosting-biogen-s-leqembi-prospects 2025-10-02T01:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-fortress-biotech-s-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-02T01:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-fortress-biotech-s-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-02T01:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/hypha-labs-and-tryptomics-advance-biotechnology-partnership-for-pharmaceutical-grade-mushroom-production 2025-10-02T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypha-labs-and-tryptomics-advance-biotechnology-partnership-for-pharmaceutical-grade-mushroom-production 2025-10-02T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-mm120-lsd-demonstrates-sustained-anxiety-relief-in-phase-2b-gad-trial 2025-10-01T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-mm120-lsd-demonstrates-sustained-anxiety-relief-in-phase-2b-gad-trial 2025-10-01T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/pace-c-trial-reveals-higher-urinary-toxicity-with-sbrt-compared-to-conventional-radiotherapy-in-prostate-cancer 2025-10-01T21:16:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pace-c-trial-reveals-higher-urinary-toxicity-with-sbrt-compared-to-conventional-radiotherapy-in-prostate-cancer 2025-10-01T21:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/rheumagen-unveils-universal-hla-gene-editing-approach-for-autoimmune-disease-treatment 2025-10-01T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rheumagen-unveils-universal-hla-gene-editing-approach-for-autoimmune-disease-treatment 2025-10-01T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-integrating-real-world-data-and-ai-for-enhanced-cell-and-gene-therapy-postmarket-surveillance 2025-10-01T21:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-integrating-real-world-data-and-ai-for-enhanced-cell-and-gene-therapy-postmarket-surveillance 2025-10-01T21:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-exits-cell-therapy-research-takes-395-million-impairment-loss 2025-10-01T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-exits-cell-therapy-research-takes-395-million-impairment-loss 2025-10-01T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/alivegen-s-alg-801-demonstrates-superior-efficacy-over-standard-pah-therapies-in-preclinical-studies 2025-10-01T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivegen-s-alg-801-demonstrates-superior-efficacy-over-standard-pah-therapies-in-preclinical-studies 2025-10-01T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/keyron-s-forepass-device-shows-8x-greater-weight-control-than-semaglutide-in-head-to-head-study 2025-10-01T17:26:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keyron-s-forepass-device-shows-8x-greater-weight-control-than-semaglutide-in-head-to-head-study 2025-10-01T17:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-strengthens-scientific-advisory-board-with-two-leading-duke-neuro-oncologists 2025-10-01T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-strengthens-scientific-advisory-board-with-two-leading-duke-neuro-oncologists 2025-10-01T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/folia-health-raises-10-5m-series-a-to-advance-patient-driven-real-world-evidence-platform 2025-10-01T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/folia-health-raises-10-5m-series-a-to-advance-patient-driven-real-world-evidence-platform 2025-10-01T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/17-year-study-demonstrates-hpv-vaccine-s-real-world-effectiveness-and-herd-immunity-protection 2025-10-01T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/17-year-study-demonstrates-hpv-vaccine-s-real-world-effectiveness-and-herd-immunity-protection 2025-10-01T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/cellphire-s-frozen-platelet-therapy-clph-511-meets-primary-endpoint-in-phase-2-3-cryptics-trial 2025-10-01T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellphire-s-frozen-platelet-therapy-clph-511-meets-primary-endpoint-in-phase-2-3-cryptics-trial 2025-10-01T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/camp4-therapeutics-advances-syngap1-gene-therapy-toward-clinical-testing-with-glp-toxicology-studies 2025-10-01T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camp4-therapeutics-advances-syngap1-gene-therapy-toward-clinical-testing-with-glp-toxicology-studies 2025-10-01T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/empatica-acquires-pkg-health-to-advance-digital-parkinson-s-disease-monitoring 2025-10-01T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empatica-acquires-pkg-health-to-advance-digital-parkinson-s-disease-monitoring 2025-10-01T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/spur-therapeutics-to-present-long-term-durability-data-for-phase-3-ready-gaucher-disease-gene-therapy 2025-10-01T17:17:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spur-therapeutics-to-present-long-term-durability-data-for-phase-3-ready-gaucher-disease-gene-therapy 2025-10-01T17:17:02+00:00 hourly 0.9 https://trial.medpath.com/news/aerska-raises-21m-to-develop-rna-therapies-for-brain-diseases-using-novel-delivery-platform 2025-10-01T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerska-raises-21m-to-develop-rna-therapies-for-brain-diseases-using-novel-delivery-platform 2025-10-01T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/omniabio-partners-with-brainchild-bio-to-manufacture-car-t-therapy-for-fatal-pediatric-brain-cancer 2025-10-01T17:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omniabio-partners-with-brainchild-bio-to-manufacture-car-t-therapy-for-fatal-pediatric-brain-cancer 2025-10-01T17:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-cutx-101-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-01T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-cutx-101-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-01T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-targets-h2-2025-fda-submission-for-sublingual-aspirin-following-positive-clinical-results 2025-10-01T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-targets-h2-2025-fda-submission-for-sublingual-aspirin-following-positive-clinical-results 2025-10-01T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/halozyme-acquires-elektrofi-for-750m-to-expand-ultra-high-concentration-drug-delivery-technology 2025-10-01T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halozyme-acquires-elektrofi-for-750m-to-expand-ultra-high-concentration-drug-delivery-technology 2025-10-01T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/cd47-inhibitor-pipeline-expands-to-over-80-drugs-as-market-anticipates-first-approval-by-2028 2025-10-01T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd47-inhibitor-pipeline-expands-to-over-80-drugs-as-market-anticipates-first-approval-by-2028 2025-10-01T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/japan-emerges-as-second-choice-market-for-orphan-drug-launches-new-analysis-reveals 2025-10-01T17:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-emerges-as-second-choice-market-for-orphan-drug-launches-new-analysis-reveals 2025-10-01T17:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-heart-rate-variability-patch-reduces-substance-use-by-64-in-recovery-patients 2025-10-01T17:13:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-heart-rate-variability-patch-reduces-substance-use-by-64-in-recovery-patients 2025-10-01T17:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/reflexion-s-scintix-platform-achieves-100-local-control-in-lung-and-bone-metastases-trial 2025-10-01T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reflexion-s-scintix-platform-achieves-100-local-control-in-lung-and-bone-metastases-trial 2025-10-01T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-m-a-activity-surges-in-q3-2025-with-55-7-billion-in-acquisitions 2025-10-01T13:17:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-m-a-activity-surges-in-q3-2025-with-55-7-billion-in-acquisitions 2025-10-01T13:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-anti-tau-antibody-bms-986446-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-10-01T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-anti-tau-antibody-bms-986446-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-10-01T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/appili-therapeutics-secures-40-million-niaid-contract-to-develop-first-in-class-fungal-vaccine-vxv-01 2025-10-01T13:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appili-therapeutics-secures-40-million-niaid-contract-to-develop-first-in-class-fungal-vaccine-vxv-01 2025-10-01T13:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-daiichi-s-raludotatug-deruxtecan-shows-51-response-rate-in-platinum-resistant-ovarian-cancer 2025-10-01T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-daiichi-s-raludotatug-deruxtecan-shows-51-response-rate-in-platinum-resistant-ovarian-cancer 2025-10-01T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-launches-piasky-as-taiwan-s-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-10-01T13:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-launches-piasky-as-taiwan-s-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-10-01T13:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-form-ai-consortium-to-accelerate-drug-discovery-through-federated-data-sharing 2025-10-01T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-form-ai-consortium-to-accelerate-drug-discovery-through-federated-data-sharing 2025-10-01T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-submits-first-indian-developed-antibiotic-to-us-fda-for-multidrug-resistant-uti-treatment 2025-10-01T13:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-submits-first-indian-developed-antibiotic-to-us-fda-for-multidrug-resistant-uti-treatment 2025-10-01T13:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/taho-pharma-submits-world-s-first-apixaban-oral-dissolving-film-to-fda-for-stroke-survivors-with-swallowing-difficulties 2025-10-01T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taho-pharma-submits-world-s-first-apixaban-oral-dissolving-film-to-fda-for-stroke-survivors-with-swallowing-difficulties 2025-10-01T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-court-blocks-glenmark-s-early-generic-eltrombopag-launch-reinforces-spc-protection 2025-10-01T09:24:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dutch-court-blocks-glenmark-s-early-generic-eltrombopag-launch-reinforces-spc-protection 2025-10-01T09:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-arizona-researchers-develop-long-acting-opioid-overdose-reversal-agent 2025-10-01T09:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-arizona-researchers-develop-long-acting-opioid-overdose-reversal-agent 2025-10-01T09:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-for-leniolisib-in-children-with-rare-immunodeficiency-apds 2025-10-01T09:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-leniolisib-in-children-with-rare-immunodeficiency-apds 2025-10-01T09:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/predictmedix-ai-launches-clinical-trial-ai-platform-to-optimize-pharmaceutical-development 2025-10-01T09:12:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictmedix-ai-launches-clinical-trial-ai-platform-to-optimize-pharmaceutical-development 2025-10-01T09:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-raises-65-million-in-upsized-public-offering-to-advance-rsv-and-immunology-pipeline 2025-10-01T05:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-raises-65-million-in-upsized-public-offering-to-advance-rsv-and-immunology-pipeline 2025-10-01T05:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-appoints-eric-olson-as-chief-business-officer-to-lead-rare-disease-pipeline-expansion 2025-10-01T05:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-appoints-eric-olson-as-chief-business-officer-to-lead-rare-disease-pipeline-expansion 2025-10-01T05:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-shows-engineered-exosomes-safely-target-kras-g12d-in-pancreatic-cancer 2025-10-01T05:12:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-shows-engineered-exosomes-safely-target-kras-g12d-in-pancreatic-cancer 2025-10-01T05:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/emagene-life-partners-with-institute-for-functional-medicine-to-launch-ai-driven-healthcare-platform-in-asia 2025-10-01T05:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emagene-life-partners-with-institute-for-functional-medicine-to-launch-ai-driven-healthcare-platform-in-asia 2025-10-01T05:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-warns-against-forced-onshoring-as-tariffs-threaten-generic-and-biosimilar-efficiency 2025-10-01T03:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-warns-against-forced-onshoring-as-tariffs-threaten-generic-and-biosimilar-efficiency 2025-10-01T03:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-scientists-create-functional-human-eggs-from-skin-cells-using-novel-mitomeiosis-technique 2025-10-01T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohsu-scientists-create-functional-human-eggs-from-skin-cells-using-novel-mitomeiosis-technique 2025-10-01T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/medera-strengthens-leadership-team-with-three-key-executive-appointments-to-advance-cardiac-gene-therapy-pipeline 2025-10-01T01:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-strengthens-leadership-team-with-three-key-executive-appointments-to-advance-cardiac-gene-therapy-pipeline 2025-10-01T01:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-advances-bispecific-adc-development-with-sunrock-biopharma-s-anti-her2-her3-antibody-license 2025-10-01T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-advances-bispecific-adc-development-with-sunrock-biopharma-s-anti-her2-her3-antibody-license 2025-10-01T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/pricing-negotiations-for-car-t-therapy-carvykti-collapse-in-canada-leaving-multiple-myeloma-patients-without-access 2025-10-01T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pricing-negotiations-for-car-t-therapy-carvykti-collapse-in-canada-leaving-multiple-myeloma-patients-without-access 2025-10-01T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/vidac-pharma-secures-broad-u-s-patent-protection-for-novel-mitochondria-targeted-cancer-therapy 2025-10-01T01:22:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vidac-pharma-secures-broad-u-s-patent-protection-for-novel-mitochondria-targeted-cancer-therapy 2025-10-01T01:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/moffitt-cancer-center-reports-promising-results-for-avelumab-radiation-combination-in-leptomeningeal-disease 2025-10-01T01:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moffitt-cancer-center-reports-promising-results-for-avelumab-radiation-combination-in-leptomeningeal-disease 2025-10-01T01:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-expands-global-single-cell-sequencing-access-through-strategic-service-provider-partnerships 2025-10-01T01:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parse-biosciences-expands-global-single-cell-sequencing-access-through-strategic-service-provider-partnerships 2025-10-01T01:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/proton-therapy-shows-survival-benefit-in-glioblastoma-trial-advances-to-phase-iii 2025-10-01T01:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-therapy-shows-survival-benefit-in-glioblastoma-trial-advances-to-phase-iii 2025-10-01T01:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/first-fda-approved-neuropixels-study-targets-executive-function-deficits-in-parkinson-s-disease 2025-10-01T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-fda-approved-neuropixels-study-targets-executive-function-deficits-in-parkinson-s-disease 2025-10-01T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/indivior-halts-marketing-of-controversial-overdose-drug-opvee-following-new-york-settlement 2025-10-01T01:17:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indivior-halts-marketing-of-controversial-overdose-drug-opvee-following-new-york-settlement 2025-10-01T01:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-remibrutinib-as-first-oral-btk-inhibitor-for-chronic-spontaneous-urticaria 2025-10-01T01:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-remibrutinib-as-first-oral-btk-inhibitor-for-chronic-spontaneous-urticaria 2025-10-01T01:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/adagio-medical-s-ultra-low-temperature-cryoablation-shows-97-acute-success-rate-in-pivotal-ventricular-tachycardia-trial 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagio-medical-s-ultra-low-temperature-cryoablation-shows-97-acute-success-rate-in-pivotal-ventricular-tachycardia-trial 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prima-retinal-implant-restores-central-vision-in-geographic-atrophy-patients-achieving-81-response-rate 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prima-retinal-implant-restores-central-vision-in-geographic-atrophy-patients-achieving-81-response-rate 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-bio-partners-with-kyorin-for-105m-hb2198-autoimmune-deal-in-japan 2025-09-30T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hinge-bio-partners-with-kyorin-for-105m-hb2198-autoimmune-deal-in-japan 2025-09-30T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-halts-new-drug-application-acceptance-as-government-shutdown-begins 2025-09-30T21:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-halts-new-drug-application-acceptance-as-government-shutdown-begins 2025-09-30T21:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-and-sanofi-expand-partnership-to-include-matrix-m-adjuvant-in-pandemic-influenza-vaccine-development 2025-09-30T21:18:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-and-sanofi-expand-partnership-to-include-matrix-m-adjuvant-in-pandemic-influenza-vaccine-development 2025-09-30T21:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-key-adverse-event-patterns-for-lutetium-177-psma-617-in-advanced-prostate-cancer 2025-09-30T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-key-adverse-event-patterns-for-lutetium-177-psma-617-in-advanced-prostate-cancer 2025-09-30T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-sixth-generation-troponin-t-test-demonstrates-high-precision-in-heart-attack-diagnosis 2025-09-30T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-sixth-generation-troponin-t-test-demonstrates-high-precision-in-heart-attack-diagnosis 2025-09-30T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-partners-with-gubra-for-preclinical-obesity-trials-of-trpv1-inhibitor-xen-d0501 2025-09-30T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-partners-with-gubra-for-preclinical-obesity-trials-of-trpv1-inhibitor-xen-d0501 2025-09-30T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/kaia-health-and-medimprove-launch-digital-copd-rehabilitation-pilot-at-ers-2025 2025-09-30T21:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaia-health-and-medimprove-launch-digital-copd-rehabilitation-pilot-at-ers-2025 2025-09-30T21:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-pd-l1-adc-hlx43-receives-fda-orphan-drug-designation-for-thymic-epithelial-tumors 2025-09-30T21:15:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-pd-l1-adc-hlx43-receives-fda-orphan-drug-designation-for-thymic-epithelial-tumors 2025-09-30T21:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/affluent-medical-advances-three-medical-device-programs-with-pivotal-trial-launch-and-fda-regulatory-progress 2025-09-30T21:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affluent-medical-advances-three-medical-device-programs-with-pivotal-trial-launch-and-fda-regulatory-progress 2025-09-30T21:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-partners-with-roche-to-deploy-digital-pathology-technology-amid-growing-pathologist-shortage 2025-09-30T17:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-partners-with-roche-to-deploy-digital-pathology-technology-amid-growing-pathologist-shortage 2025-09-30T17:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-completes-corporate-rebranding-with-focus-on-ai-powered-drug-discovery-and-parkinson-s-research 2025-09-30T17:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-completes-corporate-rebranding-with-focus-on-ai-powered-drug-discovery-and-parkinson-s-research 2025-09-30T17:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-gene-signature-tests-transform-infection-diagnosis-and-critical-care-treatment 2025-09-30T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-gene-signature-tests-transform-infection-diagnosis-and-critical-care-treatment 2025-09-30T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/biolegacy-files-patent-for-revolutionary-air-driven-intranasal-drug-delivery-platform 2025-09-30T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolegacy-files-patent-for-revolutionary-air-driven-intranasal-drug-delivery-platform 2025-09-30T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-radcomp-trial-shows-proton-and-photon-radiation-therapies-deliver-equivalent-quality-of-life-for-breast-cancer-patients 2025-09-30T17:30:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-radcomp-trial-shows-proton-and-photon-radiation-therapies-deliver-equivalent-quality-of-life-for-breast-cancer-patients 2025-09-30T17:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/addf-releases-speechdx-dataset-to-advance-ai-powered-alzheimer-s-detection-through-speech-biomarkers 2025-09-30T17:30:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addf-releases-speechdx-dataset-to-advance-ai-powered-alzheimer-s-detection-through-speech-biomarkers 2025-09-30T17:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reverses-position-on-nmn-declares-supplement-ingredient-lawful-after-industry-legal-challenge 2025-09-30T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reverses-position-on-nmn-declares-supplement-ingredient-lawful-after-industry-legal-challenge 2025-09-30T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-expanded-access-programs-for-jaguar-health-s-crofelemer-in-rare-pediatric-intestinal-disease 2025-09-30T17:27:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-expanded-access-programs-for-jaguar-health-s-crofelemer-in-rare-pediatric-intestinal-disease 2025-09-30T17:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/insufficient-source-material-prevents-comprehensive-oncology-pipeline-analysis 2025-09-30T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insufficient-source-material-prevents-comprehensive-oncology-pipeline-analysis 2025-09-30T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ub-vv111-first-in-vivo-car-t-therapy-for-relapsed-b-cell-malignancies 2025-09-30T17:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-ub-vv111-first-in-vivo-car-t-therapy-for-relapsed-b-cell-malignancies 2025-09-30T17:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-secures-fda-type-c-meeting-to-advance-mtx-001-wound-healing-therapy 2025-09-30T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merakris-therapeutics-secures-fda-type-c-meeting-to-advance-mtx-001-wound-healing-therapy 2025-09-30T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-announces-r-d-day-to-showcase-phase-3-aml-trial-results-and-cdk9-inhibitor-program 2025-09-30T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-life-sciences-announces-r-d-day-to-showcase-phase-3-aml-trial-results-and-cdk9-inhibitor-program 2025-09-30T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/benchsci-partners-with-thermo-fisher-scientific-to-deploy-ai-powered-drug-discovery-tools 2025-09-30T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benchsci-partners-with-thermo-fisher-scientific-to-deploy-ai-powered-drug-discovery-tools 2025-09-30T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-advances-broad-spectrum-antiviral-nv-387-to-phase-ii-trials-for-mpox-and-respiratory-infections 2025-09-30T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-advances-broad-spectrum-antiviral-nv-387-to-phase-ii-trials-for-mpox-and-respiratory-infections 2025-09-30T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/kynexis-initiates-phase-2-trial-of-first-in-class-kat-ii-inhibitor-for-schizophrenia-associated-cognitive-impairment 2025-09-30T17:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kynexis-initiates-phase-2-trial-of-first-in-class-kat-ii-inhibitor-for-schizophrenia-associated-cognitive-impairment 2025-09-30T17:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/inflammatix-publishes-breakthrough-sepsis-research-in-nature-medicine-validates-ai-powered-triverity-test 2025-09-30T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammatix-publishes-breakthrough-sepsis-research-in-nature-medicine-validates-ai-powered-triverity-test 2025-09-30T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-submits-fda-application-for-pivekimab-sunirine-to-treat-rare-blood-cancer-bpdcn 2025-09-30T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-submits-fda-application-for-pivekimab-sunirine-to-treat-rare-blood-cancer-bpdcn 2025-09-30T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/chosa-s-platinum-drug-predictor-shows-promise-across-multiple-cancer-types-in-clinical-validation-studies 2025-09-30T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chosa-s-platinum-drug-predictor-shows-promise-across-multiple-cancer-types-in-clinical-validation-studies 2025-09-30T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-receives-fda-breakthrough-device-designation-for-multi-condition-ai-triage-system 2025-09-30T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aidoc-receives-fda-breakthrough-device-designation-for-multi-condition-ai-triage-system 2025-09-30T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/zenflow-receives-fda-510-k-clearance-for-first-single-use-cystoscope-with-largest-working-channel 2025-09-30T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenflow-receives-fda-510-k-clearance-for-first-single-use-cystoscope-with-largest-working-channel 2025-09-30T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-completes-patient-enrollment-for-frontotemporal-dementia-combination-therapy-study 2025-09-30T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-completes-patient-enrollment-for-frontotemporal-dementia-combination-therapy-study 2025-09-30T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/zoll-zenix-monitor-defibrillator-receives-fda-approval-for-advanced-emergency-care 2025-09-30T17:19:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoll-zenix-monitor-defibrillator-receives-fda-approval-for-advanced-emergency-care 2025-09-30T17:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-bridges-clinical-trial-gaps-in-colorectal-cancer-treatment-selection 2025-09-30T17:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-bridges-clinical-trial-gaps-in-colorectal-cancer-treatment-selection 2025-09-30T17:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/crystalys-therapeutics-emerges-with-205m-series-a-to-advance-gout-treatment-dotinurad 2025-09-30T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crystalys-therapeutics-emerges-with-205m-series-a-to-advance-gout-treatment-dotinurad 2025-09-30T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-faces-regulatory-setback-as-fda-meeting-fails-to-establish-govorestat-approval-pathway 2025-09-30T13:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-faces-regulatory-setback-as-fda-meeting-fails-to-establish-govorestat-approval-pathway 2025-09-30T13:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-pharmaceuticals-raises-150-million-to-advance-duravyu-phase-3-trials-for-retinal-diseases 2025-09-30T13:18:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-raises-150-million-to-advance-duravyu-phase-3-trials-for-retinal-diseases 2025-09-30T13:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-secures-125-million-series-d-to-advance-vga039-phase-3-trial-for-von-willebrand-disease 2025-09-30T13:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-therapeutics-secures-125-million-series-d-to-advance-vga039-phase-3-trial-for-von-willebrand-disease 2025-09-30T13:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-secures-125m-series-d-to-advance-von-willebrand-disease-drug-vga039-through-phase-3-testing 2025-09-30T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-therapeutics-secures-125m-series-d-to-advance-von-willebrand-disease-drug-vga039-through-phase-3-testing 2025-09-30T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-cuts-workforce-by-50-following-fda-rejection-of-cancer-drug-application 2025-09-30T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-cuts-workforce-by-50-following-fda-rejection-of-cancer-drug-application 2025-09-30T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-ren-based-migraine-wearable-device-opening-new-treatment-pathway-for-130-million-patients 2025-09-30T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-ren-based-migraine-wearable-device-opening-new-treatment-pathway-for-130-million-patients 2025-09-30T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/acurx-receives-ema-approval-for-pediatric-investigation-plan-for-ibezapolstat-in-c-difficile-infection 2025-09-30T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurx-receives-ema-approval-for-pediatric-investigation-plan-for-ibezapolstat-in-c-difficile-infection 2025-09-30T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cs-1103-for-methamphetamine-overdose-treatment 2025-09-30T13:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-cs-1103-for-methamphetamine-overdose-treatment 2025-09-30T13:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-submits-cenobamate-application-in-japan-following-successful-phase-3-trial 2025-09-30T13:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-submits-cenobamate-application-in-japan-following-successful-phase-3-trial 2025-09-30T13:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/orion-discontinues-odm-105-development-after-phase-2-insomnia-trial-fails-to-meet-primary-endpoints 2025-09-30T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-discontinues-odm-105-development-after-phase-2-insomnia-trial-fails-to-meet-primary-endpoints 2025-09-30T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-specific-mhc-ii-expression-emerges-as-predictive-biomarker-for-immunotherapy-response-in-triple-negative-breast-cancer 2025-09-30T09:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-specific-mhc-ii-expression-emerges-as-predictive-biomarker-for-immunotherapy-response-in-triple-negative-breast-cancer 2025-09-30T09:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/vicore-pharma-s-buloxibutid-receives-orphan-drug-designation-in-japan-for-idiopathic-pulmonary-fibrosis-treatment 2025-09-30T09:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicore-pharma-s-buloxibutid-receives-orphan-drug-designation-in-japan-for-idiopathic-pulmonary-fibrosis-treatment 2025-09-30T09:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-s-nafithromycin-faces-nppa-pricing-exemption-hurdle-over-patent-validity-questions 2025-09-30T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-s-nafithromycin-faces-nppa-pricing-exemption-hurdle-over-patent-validity-questions 2025-09-30T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-bart-trial-shows-adjuvant-radiation-therapy-significantly-reduces-pelvic-recurrence-in-high-risk-bladder-cancer 2025-09-30T05:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-bart-trial-shows-adjuvant-radiation-therapy-significantly-reduces-pelvic-recurrence-in-high-risk-bladder-cancer 2025-09-30T05:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/sugemalimab-plus-chemotherapy-shows-clinical-promise-but-lacks-cost-effectiveness-in-advanced-gastric-cancer 2025-09-30T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sugemalimab-plus-chemotherapy-shows-clinical-promise-but-lacks-cost-effectiveness-in-advanced-gastric-cancer 2025-09-30T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-alzheimer-s-drug-thn391-targets-fibrin-protein-in-first-in-human-trial 2025-09-30T05:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-alzheimer-s-drug-thn391-targets-fibrin-protein-in-first-in-human-trial 2025-09-30T05:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/full-life-technologies-secures-77-million-series-c-to-advance-radiopharmaceutical-pipeline-and-manufacturing 2025-09-30T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/full-life-technologies-secures-77-million-series-c-to-advance-radiopharmaceutical-pipeline-and-manufacturing 2025-09-30T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-secures-patent-protection-for-bioengineered-esophagus-through-2041 2025-09-30T05:13:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-secures-patent-protection-for-bioengineered-esophagus-through-2041 2025-09-30T05:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-s-dmx-200-receives-orphan-drug-designation-in-japan-for-rare-kidney-disease-treatment 2025-09-30T05:13:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-s-dmx-200-receives-orphan-drug-designation-in-japan-for-rare-kidney-disease-treatment 2025-09-30T05:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-ttfields-therapy-significantly-delays-brain-metastasis-progression-in-nsclc-patients-following-stereotactic-radiosurgery 2025-09-30T05:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-ttfields-therapy-significantly-delays-brain-metastasis-progression-in-nsclc-patients-following-stereotactic-radiosurgery 2025-09-30T05:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/remote-monitoring-reduces-pediatric-asthma-hospitalizations-by-58-in-dutch-multicentre-study 2025-09-30T01:20:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-monitoring-reduces-pediatric-asthma-hospitalizations-by-58-in-dutch-multicentre-study 2025-09-30T01:20:43+00:00 hourly 0.9 https://trial.medpath.com/news/anaptysbio-plans-corporate-split-to-separate-royalty-assets-from-drug-development-operations 2025-09-30T01:18:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anaptysbio-plans-corporate-split-to-separate-royalty-assets-from-drug-development-operations 2025-09-30T01:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/danicamtiv-shows-promise-in-phase-2a-trial-for-genetic-dilated-cardiomyopathy 2025-09-30T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danicamtiv-shows-promise-in-phase-2a-trial-for-genetic-dilated-cardiomyopathy 2025-09-30T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-cuts-33-of-workforce-to-extend-cash-runway-through-adc-development-milestones 2025-09-30T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-cuts-33-of-workforce-to-extend-cash-runway-through-adc-development-milestones 2025-09-30T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/biodegradable-brain-implants-show-promise-in-preventing-glioblastoma-recurrence-through-immune-system-reprogramming 2025-09-30T01:14:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodegradable-brain-implants-show-promise-in-preventing-glioblastoma-recurrence-through-immune-system-reprogramming 2025-09-30T01:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/led-based-photobiomodulation-device-shows-70-reduction-in-severe-oral-mucositis-for-head-and-neck-cancer-patients 2025-09-30T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/led-based-photobiomodulation-device-shows-70-reduction-in-severe-oral-mucositis-for-head-and-neck-cancer-patients 2025-09-30T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-five-treatment-radiation-regimen-improves-quality-of-life-for-prostate-cancer-patients 2025-09-30T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-five-treatment-radiation-regimen-improves-quality-of-life-for-prostate-cancer-patients 2025-09-30T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/ars-pharmaceuticals-secures-250-million-loan-facility-to-accelerate-neffy-commercialization 2025-09-30T01:14:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ars-pharmaceuticals-secures-250-million-loan-facility-to-accelerate-neffy-commercialization 2025-09-30T01:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-appoints-keith-gottesdiener-as-board-director-and-r-d-committee-chair 2025-09-30T01:13:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septerna-appoints-keith-gottesdiener-as-board-director-and-r-d-committee-chair 2025-09-30T01:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/locus-cell-secures-first-international-phase-iii-cdmo-partnership-with-cambium-bio-for-dry-eye-therapy 2025-09-30T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/locus-cell-secures-first-international-phase-iii-cdmo-partnership-with-cambium-bio-for-dry-eye-therapy 2025-09-30T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-surgical-receives-fda-510-k-clearance-for-revolutionary-hybrid-endoscope-system 2025-09-30T01:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-surgical-receives-fda-510-k-clearance-for-revolutionary-hybrid-endoscope-system 2025-09-30T01:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-rmat-guidance-to-accelerate-regenerative-medicine-development 2025-09-30T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-rmat-guidance-to-accelerate-regenerative-medicine-development 2025-09-30T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/gammacore-non-invasive-vagus-nerve-stimulation-shows-promise-for-persistent-post-concussion-symptoms-in-102-patient-study 2025-09-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gammacore-non-invasive-vagus-nerve-stimulation-shows-promise-for-persistent-post-concussion-symptoms-in-102-patient-study 2025-09-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-director-criticizes-lupus-nephritis-drug-lupkynis-questions-surrogate-endpoint-approvals 2025-09-29T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-director-criticizes-lupus-nephritis-drug-lupkynis-questions-surrogate-endpoint-approvals 2025-09-29T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/conflicting-results-emerge-from-two-major-trials-comparing-proton-beam-therapy-to-imrt-for-head-and-neck-cancer 2025-09-29T21:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conflicting-results-emerge-from-two-major-trials-comparing-proton-beam-therapy-to-imrt-for-head-and-neck-cancer 2025-09-29T21:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-adebrelimab-efficacy-in-extensive-stage-small-cell-lung-cancer 2025-09-29T21:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-adebrelimab-efficacy-in-extensive-stage-small-cell-lung-cancer 2025-09-29T21:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/chlorate-antibiotic-combination-shows-10000-fold-increase-in-efficacy-against-chronic-wound-infections 2025-09-29T21:14:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chlorate-antibiotic-combination-shows-10000-fold-increase-in-efficacy-against-chronic-wound-infections 2025-09-29T21:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/jr-446-receives-japanese-orphan-drug-designation-for-rare-sanfilippo-syndrome-type-b 2025-09-29T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jr-446-receives-japanese-orphan-drug-designation-for-rare-sanfilippo-syndrome-type-b 2025-09-29T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-demonstrates-enhanced-tumor-control-with-novel-bnct-immunotherapy-combination-in-preclinical-studies 2025-09-29T21:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tae-life-sciences-demonstrates-enhanced-tumor-control-with-novel-bnct-immunotherapy-combination-in-preclinical-studies 2025-09-29T21:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-promise-for-probiotic-bl21-in-preventing-radiation-induced-enteritis 2025-09-29T21:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-promise-for-probiotic-bl21-in-preventing-radiation-induced-enteritis 2025-09-29T21:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/accendatech-initiates-phase-3-trial-of-act001-for-small-cell-lung-cancer-with-brain-metastasis 2025-09-29T21:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accendatech-initiates-phase-3-trial-of-act001-for-small-cell-lung-cancer-with-brain-metastasis 2025-09-29T21:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/angiosafe-s-santreva-atk-receives-fda-clearance-for-peripheral-artery-disease-treatment 2025-09-29T21:11:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angiosafe-s-santreva-atk-receives-fda-clearance-for-peripheral-artery-disease-treatment 2025-09-29T21:11:51+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-based-drug-shows-significant-pain-relief-in-large-clinical-trial-for-chronic-lower-back-pain 2025-09-29T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-based-drug-shows-significant-pain-relief-in-large-clinical-trial-for-chronic-lower-back-pain 2025-09-29T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/affluent-medical-s-artus-robotic-urinary-sphincter-shows-87-improvement-in-pilot-trial-results 2025-09-29T21:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affluent-medical-s-artus-robotic-urinary-sphincter-shows-87-improvement-in-pilot-trial-results 2025-09-29T21:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-shows-promise-in-teen-hs-patients-despite-adult-trial-setbacks 2025-09-29T21:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-s-sonelokimab-shows-promise-in-teen-hs-patients-despite-adult-trial-setbacks 2025-09-29T21:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-reports-promising-results-for-certepetide-in-pancreatic-cancer-trial 2025-09-29T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-reports-promising-results-for-certepetide-in-pancreatic-cancer-trial 2025-09-29T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/aarvik-therapeutics-secures-series-seed-2-funding-to-advance-next-generation-adc-platform 2025-09-29T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aarvik-therapeutics-secures-series-seed-2-funding-to-advance-next-generation-adc-platform 2025-09-29T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-secures-exclusive-global-rights-to-first-in-class-p-glycoprotein-inhibitor-encequidar 2025-09-29T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-secures-exclusive-global-rights-to-first-in-class-p-glycoprotein-inhibitor-encequidar 2025-09-29T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/gi-innovation-receives-fda-fast-track-designation-for-gi-102-melanoma-therapy 2025-09-29T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-innovation-receives-fda-fast-track-designation-for-gi-102-melanoma-therapy 2025-09-29T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/iqure-pharma-secures-us-patent-for-first-in-class-cns-drug-iq-007-targeting-glutamate-excitotoxicity 2025-09-29T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqure-pharma-secures-us-patent-for-first-in-class-cns-drug-iq-007-targeting-glutamate-excitotoxicity 2025-09-29T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trilynx-trial-shows-xevinapant-worsens-outcomes-in-head-and-neck-cancer-patients 2025-09-29T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trilynx-trial-shows-xevinapant-worsens-outcomes-in-head-and-neck-cancer-patients 2025-09-29T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-completes-phase-1-trial-of-topical-curcumin-gel-vas-101-for-knee-osteoarthritis 2025-09-29T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascarta-completes-phase-1-trial-of-topical-curcumin-gel-vas-101-for-knee-osteoarthritis 2025-09-29T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-appoints-alan-sandler-as-chief-development-officer-to-advance-ras-targeted-cancer-pipeline 2025-09-29T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-appoints-alan-sandler-as-chief-development-officer-to-advance-ras-targeted-cancer-pipeline 2025-09-29T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-reports-strong-growth-across-oncology-portfolio-with-44-revenue-increase 2025-09-29T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-reports-strong-growth-across-oncology-portfolio-with-44-revenue-increase 2025-09-29T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-secures-343-5-million-to-launch-world-s-first-strategic-compute-reserve-for-ai-drug-discovery 2025-09-29T17:20:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-secures-343-5-million-to-launch-world-s-first-strategic-compute-reserve-for-ai-drug-discovery 2025-09-29T17:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-biopharmaceuticals-launches-preclinical-study-of-oral-pv-10-for-bladder-cancer-treatment 2025-09-29T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/provectus-biopharmaceuticals-launches-preclinical-study-of-oral-pv-10-for-bladder-cancer-treatment 2025-09-29T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-appoints-dr-usman-azam-as-ceo-pivots-to-autoimmune-disease-focus-with-cue-401 2025-09-29T17:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-appoints-dr-usman-azam-as-ceo-pivots-to-autoimmune-disease-focus-with-cue-401 2025-09-29T17:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/xenopax-demonstrates-superior-efficacy-in-steroid-refractory-acute-gvhd-treatment 2025-09-29T17:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenopax-demonstrates-superior-efficacy-in-steroid-refractory-acute-gvhd-treatment 2025-09-29T17:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/rome-trial-demonstrates-precision-oncology-benefits-in-advanced-solid-tumors 2025-09-29T17:17:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rome-trial-demonstrates-precision-oncology-benefits-in-advanced-solid-tumors 2025-09-29T17:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-cannabis-extract-ver-01-delivers-significant-pain-relief-for-chronic-low-back-pain 2025-09-29T17:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-cannabis-extract-ver-01-delivers-significant-pain-relief-for-chronic-low-back-pain 2025-09-29T17:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-completes-phase-iii-enrollment-for-rezzayo-antifungal-prophylaxis-in-bone-marrow-transplant-patients 2025-09-29T17:16:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-completes-phase-iii-enrollment-for-rezzayo-antifungal-prophylaxis-in-bone-marrow-transplant-patients 2025-09-29T17:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-appoints-andrew-bayliffe-as-chief-development-officer-to-advance-somatic-genomics-platform 2025-09-29T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-therapeutics-appoints-andrew-bayliffe-as-chief-development-officer-to-advance-somatic-genomics-platform 2025-09-29T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/tabuk-launches-vibativ-antibiotic-in-saudi-arabia-to-combat-multidrug-resistant-infections 2025-09-29T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tabuk-launches-vibativ-antibiotic-in-saudi-arabia-to-combat-multidrug-resistant-infections 2025-09-29T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/zurnai-auto-injector-shows-superior-performance-over-intranasal-naloxone-in-fentanyl-overdose-reversal-study 2025-09-29T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zurnai-auto-injector-shows-superior-performance-over-intranasal-naloxone-in-fentanyl-overdose-reversal-study 2025-09-29T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/rezon-bio-launches-as-european-cdmo-for-biologics-with-dual-facility-operations-in-poland 2025-09-29T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezon-bio-launches-as-european-cdmo-for-biologics-with-dual-facility-operations-in-poland 2025-09-29T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-direct-to-patient-platform-for-cosentyx-with-55-discount-in-us 2025-09-29T17:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-launches-direct-to-patient-platform-for-cosentyx-with-55-discount-in-us 2025-09-29T17:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-resubmits-fda-application-for-first-once-weekly-insulin-for-type-2-diabetes 2025-09-29T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-resubmits-fda-application-for-first-once-weekly-insulin-for-type-2-diabetes 2025-09-29T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-to-launch-ovarian-cancer-drug-elahere-in-uk-at-us-list-price 2025-09-29T17:11:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-to-launch-ovarian-cancer-drug-elahere-in-uk-at-us-list-price 2025-09-29T17:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-s-clym116-shows-superior-performance-in-iga-nephropathy-preclinical-study 2025-09-29T13:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climb-bio-s-clym116-shows-superior-performance-in-iga-nephropathy-preclinical-study 2025-09-29T13:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-radiation-therapy-shows-promise-for-knee-osteoarthritis-pain-relief-in-clinical-trial 2025-09-29T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-radiation-therapy-shows-promise-for-knee-osteoarthritis-pain-relief-in-clinical-trial 2025-09-29T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-secures-29m-financing-to-advance-inhaled-mrna-therapy-for-cystic-fibrosis 2025-09-29T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-secures-29m-financing-to-advance-inhaled-mrna-therapy-for-cystic-fibrosis 2025-09-29T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-falls-short-in-hidradenitis-suppurativa-trials-shares-plummet-80 2025-09-29T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-s-sonelokimab-falls-short-in-hidradenitis-suppurativa-trials-shares-plummet-80 2025-09-29T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-secures-exclusive-license-for-sp16-cancer-pain-treatment-with-nci-funded-phase-1b-trial 2025-09-29T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-secures-exclusive-license-for-sp16-cancer-pain-treatment-with-nci-funded-phase-1b-trial 2025-09-29T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/redx-pharma-s-zelasudil-shows-promise-in-phase-2a-ipf-trial-with-47-reduction-in-lung-function-decline 2025-09-29T13:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redx-pharma-s-zelasudil-shows-promise-in-phase-2a-ipf-trial-with-47-reduction-in-lung-function-decline 2025-09-29T13:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-advances-tnx-2900-to-phase-2-trial-for-prader-willi-syndrome-following-fda-clearance 2025-09-29T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-advances-tnx-2900-to-phase-2-trial-for-prader-willi-syndrome-following-fda-clearance 2025-09-29T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/oxccu-raises-28m-series-b-to-scale-sustainable-aviation-fuel-technology-from-waste-carbon 2025-09-29T13:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxccu-raises-28m-series-b-to-scale-sustainable-aviation-fuel-technology-from-waste-carbon 2025-09-29T13:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-appoints-dr-ajay-ahuja-as-chief-medical-officer-to-advance-inhaled-therapeutics-pipeline 2025-09-29T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-appoints-dr-ajay-ahuja-as-chief-medical-officer-to-advance-inhaled-therapeutics-pipeline 2025-09-29T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-receives-fda-clearance-to-advance-rpt904-phase-2b-trial-for-food-allergy-treatment 2025-09-29T13:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-receives-fda-clearance-to-advance-rpt904-phase-2b-trial-for-food-allergy-treatment 2025-09-29T13:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/kedrion-biopharma-secures-fda-approval-for-qivigy-first-proprietary-ivig-therapy-for-primary-immunodeficiency 2025-09-29T13:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kedrion-biopharma-secures-fda-approval-for-qivigy-first-proprietary-ivig-therapy-for-primary-immunodeficiency 2025-09-29T13:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-acquires-visufarma-for-eur190-million-to-expand-european-ophthalmology-portfolio 2025-09-29T09:22:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-acquires-visufarma-for-eur190-million-to-expand-european-ophthalmology-portfolio 2025-09-29T09:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/virometix-completes-enrollment-in-phase-i-trial-of-v-212-synthetic-pneumococcal-vaccine 2025-09-29T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virometix-completes-enrollment-in-phase-i-trial-of-v-212-synthetic-pneumococcal-vaccine 2025-09-29T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/dinamiqs-opens-switzerland-s-first-cgmp-viral-vector-manufacturing-facility-partners-with-seal-therapeutics-for-muscular-dystrophy-gene-therapy 2025-09-29T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dinamiqs-opens-switzerland-s-first-cgmp-viral-vector-manufacturing-facility-partners-with-seal-therapeutics-for-muscular-dystrophy-gene-therapy 2025-09-29T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-ceo-emma-walmsley-to-step-down-luke-miels-named-successor 2025-09-29T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-ceo-emma-walmsley-to-step-down-luke-miels-named-successor 2025-09-29T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-advances-novel-sustained-release-peptide-formulations-to-preclinical-testing 2025-09-29T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinuvel-advances-novel-sustained-release-peptide-formulations-to-preclinical-testing 2025-09-29T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-accepts-nda-for-dorzagliatin-world-s-first-glucokinase-activator-for-type-2-diabetes 2025-09-29T09:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-accepts-nda-for-dorzagliatin-world-s-first-glucokinase-activator-for-type-2-diabetes 2025-09-29T09:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-poised-to-transform-pharmaceutical-r-d-through-autonomous-multi-agent-systems 2025-09-29T08:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agentic-ai-poised-to-transform-pharmaceutical-r-d-through-autonomous-multi-agent-systems 2025-09-29T08:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-reports-phase-3-teton-2-trial-results-in-conference-call 2025-09-29T01:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-reports-phase-3-teton-2-trial-results-in-conference-call 2025-09-29T01:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/pam50-biomarker-predicts-hormone-therapy-benefit-in-recurrent-prostate-cancer-balance-trial-shows 2025-09-29T01:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pam50-biomarker-predicts-hormone-therapy-benefit-in-recurrent-prostate-cancer-balance-trial-shows 2025-09-29T01:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-announces-5-2-billion-acquisition-of-merus-to-expand-late-stage-oncology-pipeline 2025-09-29T01:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-announces-5-2-billion-acquisition-of-merus-to-expand-late-stage-oncology-pipeline 2025-09-29T01:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/first-predictive-biomarker-for-hormone-therapy-in-recurrent-prostate-cancer-validated-in-phase-ii-balance-trial 2025-09-29T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-predictive-biomarker-for-hormone-therapy-in-recurrent-prostate-cancer-validated-in-phase-ii-balance-trial 2025-09-29T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/beta-technologies-files-for-825-million-ipo-to-fund-electric-aircraft-development 2025-09-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-technologies-files-for-825-million-ipo-to-fund-electric-aircraft-development 2025-09-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-unveils-gracetm-first-upright-photon-therapy-system-at-astro-2025 2025-09-28T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-cancer-care-unveils-gracetm-first-upright-photon-therapy-system-at-astro-2025 2025-09-28T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/vision-preserving-uveal-melanoma-treatment-shows-unexpected-survival-benefits-in-ucla-study 2025-09-28T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vision-preserving-uveal-melanoma-treatment-shows-unexpected-survival-benefits-in-ucla-study 2025-09-28T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-shows-mixed-results-in-phase-3-hidradenitis-suppurativa-trials 2025-09-28T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-s-sonelokimab-shows-mixed-results-in-phase-3-hidradenitis-suppurativa-trials 2025-09-28T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/altesa-biosciences-vapendavir-shows-promise-in-copd-rhinovirus-challenge-study 2025-09-28T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altesa-biosciences-vapendavir-shows-promise-in-copd-rhinovirus-challenge-study 2025-09-28T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-advances-ai-powered-cancer-drug-rec-617-to-phase-2-trial-despite-high-risk-profile 2025-09-28T17:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-advances-ai-powered-cancer-drug-rec-617-to-phase-2-trial-despite-high-risk-profile 2025-09-28T17:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-s-huntington-s-disease-gene-therapy-shows-75-reduction-in-disease-progression-pressures-ptc-therapeutics 2025-09-28T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-s-huntington-s-disease-gene-therapy-shows-75-reduction-in-disease-progression-pressures-ptc-therapeutics 2025-09-28T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/combination-inhaler-reduces-asthma-attacks-in-children-by-45-in-landmark-trial 2025-09-28T09:12:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-inhaler-reduces-asthma-attacks-in-children-by-45-in-landmark-trial 2025-09-28T09:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-bioinsight-ai-unit-and-expands-kras-companion-diagnostic-partnerships 2025-09-28T09:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-launches-bioinsight-ai-unit-and-expands-kras-companion-diagnostic-partnerships 2025-09-28T09:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-cream-achieves-positive-phase-3-results-for-atopic-dermatitis-in-china 2025-09-28T09:11:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-cream-achieves-positive-phase-3-results-for-atopic-dermatitis-in-china 2025-09-28T09:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-secures-option-to-acquire-first-in-class-on-demand-pulmonary-hypertension-therapy-rt234 2025-09-28T01:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gossamer-bio-secures-option-to-acquire-first-in-class-on-demand-pulmonary-hypertension-therapy-rt234 2025-09-28T01:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-expands-oxford-nanopore-partnership-through-2032-for-advanced-genetic-diagnostics 2025-09-28T01:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-expands-oxford-nanopore-partnership-through-2032-for-advanced-genetic-diagnostics 2025-09-28T01:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/carnegie-mellon-develops-living-microbots-from-human-lung-cells-for-targeted-drug-delivery 2025-09-28T01:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carnegie-mellon-develops-living-microbots-from-human-lung-cells-for-targeted-drug-delivery 2025-09-28T01:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-stock-surges-85-following-strong-performance-in-gene-targeted-therapies 2025-09-28T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-pharmaceuticals-stock-surges-85-following-strong-performance-in-gene-targeted-therapies 2025-09-28T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/clearpoint-neuro-appoints-dr-paul-larson-as-chief-medical-officer-and-unveils-robotic-neuro-navigation-system 2025-09-27T21:11:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearpoint-neuro-appoints-dr-paul-larson-as-chief-medical-officer-and-unveils-robotic-neuro-navigation-system 2025-09-27T21:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-tool-enables-personalized-radiation-dosing-for-hpv-positive-throat-cancer 2025-09-27T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-tool-enables-personalized-radiation-dosing-for-hpv-positive-throat-cancer 2025-09-27T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/vidofludimus-calcium-shows-promise-for-progressive-ms-despite-missing-primary-endpoint-in-phase-2-trial 2025-09-27T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vidofludimus-calcium-shows-promise-for-progressive-ms-despite-missing-primary-endpoint-in-phase-2-trial 2025-09-27T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/stream-program-delivers-actionable-genomic-insights-for-59-of-pediatric-cancer-patients-in-asia-s-first-nationwide-wgs-initiative 2025-09-27T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stream-program-delivers-actionable-genomic-insights-for-59-of-pediatric-cancer-patients-in-asia-s-first-nationwide-wgs-initiative 2025-09-27T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-raises-115-million-to-advance-oligonucleotide-therapies-for-neuromuscular-diseases 2025-09-27T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepgen-raises-115-million-to-advance-oligonucleotide-therapies-for-neuromuscular-diseases 2025-09-27T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/dmt-shows-neuroprotective-effects-in-stroke-through-blood-brain-barrier-stabilization-and-anti-inflammatory-action 2025-09-27T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dmt-shows-neuroprotective-effects-in-stroke-through-blood-brain-barrier-stabilization-and-anti-inflammatory-action 2025-09-27T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-to-present-novel-aav5-capsid-and-alpha-synuclein-targeting-therapy-for-parkinson-s-disease-at-esgct-congress 2025-09-27T09:12:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-therapeutics-to-present-novel-aav5-capsid-and-alpha-synuclein-targeting-therapy-for-parkinson-s-disease-at-esgct-congress 2025-09-27T09:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/amalee-trial-shows-400mg-ribociclib-dose-fails-to-match-600mg-efficacy-in-advanced-breast-cancer 2025-09-27T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amalee-trial-shows-400mg-ribociclib-dose-fails-to-match-600mg-efficacy-in-advanced-breast-cancer 2025-09-27T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-university-researchers-develop-first-targeted-therapy-for-rare-kidney-disease-c3g 2025-09-27T09:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newcastle-university-researchers-develop-first-targeted-therapy-for-rare-kidney-disease-c3g 2025-09-27T09:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-raises-7-5-million-in-public-offering-to-advance-rare-disease-pipeline 2025-09-27T05:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-raises-7-5-million-in-public-offering-to-advance-rare-disease-pipeline 2025-09-27T05:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-expands-35-monthly-insulin-program-to-all-americans-regardless-of-insurance-status 2025-09-27T01:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-expands-35-monthly-insulin-program-to-all-americans-regardless-of-insurance-status 2025-09-27T01:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/factor-bioscience-sues-astrazeneca-and-cellectis-over-gene-editing-patent-infringement 2025-09-27T01:18:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/factor-bioscience-sues-astrazeneca-and-cellectis-over-gene-editing-patent-infringement 2025-09-27T01:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lipid-nanoparticles-show-promise-for-non-surgical-cataract-treatment-in-rat-studies 2025-09-27T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-lipid-nanoparticles-show-promise-for-non-surgical-cataract-treatment-in-rat-studies 2025-09-27T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-direct-to-consumer-platform-offering-up-to-70-discounts-on-key-medications 2025-09-27T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-direct-to-consumer-platform-offering-up-to-70-discounts-on-key-medications 2025-09-27T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/apixaban-shows-superior-safety-profile-compared-to-rivaroxaban-in-cancer-associated-venous-thromboembolism 2025-09-27T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apixaban-shows-superior-safety-profile-compared-to-rivaroxaban-in-cancer-associated-venous-thromboembolism 2025-09-27T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-researchers-develop-novel-drug-targeting-hsp70-for-pancreatic-cancer-treatment 2025-09-27T01:15:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-cincinnati-researchers-develop-novel-drug-targeting-hsp70-for-pancreatic-cancer-treatment 2025-09-27T01:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-antibiotic-approval-pathways-balance-urgent-medical-need-with-limited-clinical-data 2025-09-27T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-antibiotic-approval-pathways-balance-urgent-medical-need-with-limited-clinical-data 2025-09-27T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-s-dm1-therapy-achieves-record-53-7-splicing-correction-in-phase-1-trial 2025-09-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepgen-s-dm1-therapy-achieves-record-53-7-splicing-correction-in-phase-1-trial 2025-09-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-direct-to-consumer-platform-with-up-to-70-drug-discounts-following-trump-administration-pressure 2025-09-26T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-direct-to-consumer-platform-with-up-to-70-drug-discounts-following-trump-administration-pressure 2025-09-26T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-t-cell-receptor-therapy-targets-ctnnb1-mutation-achieves-complete-tumor-clearance-in-preclinical-studies 2025-09-26T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-t-cell-receptor-therapy-targets-ctnnb1-mutation-achieves-complete-tumor-clearance-in-preclinical-studies 2025-09-26T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/isth0036-shows-unexpected-anti-fibrotic-and-visual-benefits-in-phase-2a-retinal-disease-trial 2025-09-26T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isth0036-shows-unexpected-anti-fibrotic-and-visual-benefits-in-phase-2a-retinal-disease-trial 2025-09-26T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/predict-rt-trial-completes-enrollment-testing-genomic-guided-treatment-strategies-for-high-risk-prostate-cancer 2025-09-26T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predict-rt-trial-completes-enrollment-testing-genomic-guided-treatment-strategies-for-high-risk-prostate-cancer 2025-09-26T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-submits-bla-for-omalizumab-biosimilar-to-challenge-4-1-billion-xolair-market 2025-09-26T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-submits-bla-for-omalizumab-biosimilar-to-challenge-4-1-billion-xolair-market 2025-09-26T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-secures-u-s-patent-for-g-csf-antibody-cancer-therapy-and-advances-multi-platform-pipeline 2025-09-26T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-secures-u-s-patent-for-g-csf-antibody-cancer-therapy-and-advances-multi-platform-pipeline 2025-09-26T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-partners-with-china-to-establish-africa-s-first-local-insulin-production-facility 2025-09-26T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-partners-with-china-to-establish-africa-s-first-local-insulin-production-facility 2025-09-26T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/kerry-inaugurates-leipzig-biotechnology-centre-to-advance-pharmaceutical-and-food-applications 2025-09-26T17:14:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kerry-inaugurates-leipzig-biotechnology-centre-to-advance-pharmaceutical-and-food-applications 2025-09-26T17:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-acquires-melt-pharmaceuticals-to-advance-non-opioid-sedation-therapy-melt-300 2025-09-26T13:16:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harrow-acquires-melt-pharmaceuticals-to-advance-non-opioid-sedation-therapy-melt-300 2025-09-26T13:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-trial-shows-promise-for-ms-myelin-repair-using-diabetes-drug-antihistamine-combination 2025-09-26T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-trial-shows-promise-for-ms-myelin-repair-using-diabetes-drug-antihistamine-combination 2025-09-26T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/who-supported-study-reveals-covid-19-vaccine-effectiveness-among-egyptian-healthcare-workers-during-omicron-era 2025-09-26T13:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-supported-study-reveals-covid-19-vaccine-effectiveness-among-egyptian-healthcare-workers-during-omicron-era 2025-09-26T13:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-100-tariffs-on-branded-pharmaceuticals-trigger-sharp-decline-in-indian-pharma-stocks 2025-09-26T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-100-tariffs-on-branded-pharmaceuticals-trigger-sharp-decline-in-indian-pharma-stocks 2025-09-26T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-approves-two-orphan-drugs-for-rare-cancers-ayvakyt-for-gist-and-mastocytosis-vanflyta-for-flt3-itd-aml 2025-09-26T13:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swissmedic-approves-two-orphan-drugs-for-rare-cancers-ayvakyt-for-gist-and-mastocytosis-vanflyta-for-flt3-itd-aml 2025-09-26T13:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/deep-eigenmatics-receives-us-patent-for-ai-driven-protein-design-method-in-drug-discovery 2025-09-26T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-eigenmatics-receives-us-patent-for-ai-driven-protein-design-method-in-drug-discovery 2025-09-26T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/concept-life-sciences-establishes-one-of-uk-s-largest-drug-discovery-research-sites-with-major-facility-expansion 2025-09-26T13:13:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-life-sciences-establishes-one-of-uk-s-largest-drug-discovery-research-sites-with-major-facility-expansion 2025-09-26T13:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/electra-battery-materials-secures-30-million-financing-for-north-america-s-first-cobalt-sulfate-refinery 2025-09-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-battery-materials-secures-30-million-financing-for-north-america-s-first-cobalt-sulfate-refinery 2025-09-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-study-confirms-rabishield-monoclonal-antibody-therapy-as-safe-effective-alternative-for-rabies-prevention 2025-09-26T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-study-confirms-rabishield-monoclonal-antibody-therapy-as-safe-effective-alternative-for-rabies-prevention 2025-09-26T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/first-successful-car-t-cell-therapy-for-multidrug-resistant-ulcerative-colitis-achieves-complete-remission 2025-09-26T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-successful-car-t-cell-therapy-for-multidrug-resistant-ulcerative-colitis-achieves-complete-remission 2025-09-26T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/cayman-chemical-partners-with-akadeum-to-distribute-revolutionary-microbubble-cell-isolation-technology 2025-09-26T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cayman-chemical-partners-with-akadeum-to-distribute-revolutionary-microbubble-cell-isolation-technology 2025-09-26T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-receives-world-s-first-pmda-approval-for-iodine-treated-hip-replacement-system 2025-09-26T09:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimmer-biomet-receives-world-s-first-pmda-approval-for-iodine-treated-hip-replacement-system 2025-09-26T09:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/roche-presents-complete-tigit-failure-data-at-esmo-2025-revealing-costly-misstep-in-cancer-immunotherapy 2025-09-26T09:20:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-presents-complete-tigit-failure-data-at-esmo-2025-revealing-costly-misstep-in-cancer-immunotherapy 2025-09-26T09:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/cadence-launches-rocs-x-ai-platform-for-drug-discovery-enabling-trillion-molecule-virtual-screening 2025-09-26T09:20:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadence-launches-rocs-x-ai-platform-for-drug-discovery-enabling-trillion-molecule-virtual-screening 2025-09-26T09:20:14+00:00 hourly 0.9 https://trial.medpath.com/news/inoviq-secures-exclusive-global-rights-to-university-of-queensland-s-ovarian-cancer-biomarker-technology 2025-09-26T05:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inoviq-secures-exclusive-global-rights-to-university-of-queensland-s-ovarian-cancer-biomarker-technology 2025-09-26T05:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-canada-partners-with-mint-pharmaceuticals-for-adalat-xl-distribution-to-strengthen-canadian-market-access 2025-09-26T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-canada-partners-with-mint-pharmaceuticals-for-adalat-xl-distribution-to-strengthen-canadian-market-access 2025-09-26T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-renu-fails-to-meet-primary-endpoint-in-second-phase-3-trial-for-knee-osteoarthritis 2025-09-26T01:28:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organogenesis-renu-fails-to-meet-primary-endpoint-in-second-phase-3-trial-for-knee-osteoarthritis 2025-09-26T01:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/uk-extends-vpag-2026-decision-deadline-to-november-14-amid-life-sciences-uncertainty 2025-09-26T01:28:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-extends-vpag-2026-decision-deadline-to-november-14-amid-life-sciences-uncertainty 2025-09-26T01:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/anebulo-pharmaceuticals-initiates-phase-i-trial-of-iv-selonabant-as-first-cannabis-toxicity-antidote 2025-09-26T01:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anebulo-pharmaceuticals-initiates-phase-i-trial-of-iv-selonabant-as-first-cannabis-toxicity-antidote 2025-09-26T01:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/n2off-stockholders-approve-acquisition-of-mitocarex-bio-targeting-mitochondrial-slc25-proteins-for-cancer-therapy 2025-09-26T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n2off-stockholders-approve-acquisition-of-mitocarex-bio-targeting-mitochondrial-slc25-proteins-for-cancer-therapy 2025-09-26T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-and-sygnature-discovery-launch-commercial-sales-of-ai-powered-drug-discovery-platform 2025-09-26T01:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-and-sygnature-discovery-launch-commercial-sales-of-ai-powered-drug-discovery-platform 2025-09-26T01:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/onconetix-and-ocuvex-terminate-merger-agreement-as-ocuvex-prepares-omlonti-commercial-launch 2025-09-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconetix-and-ocuvex-terminate-merger-agreement-as-ocuvex-prepares-omlonti-commercial-launch 2025-09-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-partners-with-university-of-wisconsin-madison-to-launch-first-us-accelerator-based-bnct-cancer-treatment-center 2025-09-25T22:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tae-life-sciences-partners-with-university-of-wisconsin-madison-to-launch-first-us-accelerator-based-bnct-cancer-treatment-center 2025-09-25T22:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/hitachi-high-tech-partners-with-elitech-to-develop-automated-pcr-platform-for-infectious-disease-testing 2025-09-25T22:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hitachi-high-tech-partners-with-elitech-to-develop-automated-pcr-platform-for-infectious-disease-testing 2025-09-25T22:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-researchers-develop-pan-cancer-immunotherapy-using-velcro-like-glycan-targeting-technology 2025-09-25T22:18:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-irvine-researchers-develop-pan-cancer-immunotherapy-using-velcro-like-glycan-targeting-technology 2025-09-25T22:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-doctors-pioneer-car-t-cell-therapy-for-severe-lupus-in-regional-first 2025-09-25T22:16:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-doctors-pioneer-car-t-cell-therapy-for-severe-lupus-in-regional-first 2025-09-25T22:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-s-nexobrid-receives-marketing-authorization-in-australia-expanding-global-burn-treatment-access 2025-09-25T22:14:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-s-nexobrid-receives-marketing-authorization-in-australia-expanding-global-burn-treatment-access 2025-09-25T22:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/kardigan-secures-254-million-series-b-to-advance-three-late-stage-cardiovascular-programs 2025-09-25T22:14:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kardigan-secures-254-million-series-b-to-advance-three-late-stage-cardiovascular-programs 2025-09-25T22:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-reports-positive-phase-iii-confides-trial-results-for-highly-sensitized-kidney-transplant-patients 2025-09-25T20:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-reports-positive-phase-iii-confides-trial-results-for-highly-sensitized-kidney-transplant-patients 2025-09-25T20:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-showcases-promising-first-in-human-data-for-kras-g12c-and-fgfr3-inhibitors 2025-09-25T20:20:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-2025-showcases-promising-first-in-human-data-for-kras-g12c-and-fgfr3-inhibitors 2025-09-25T20:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-spectacle-lens-to-slow-myopia-progression-in-children 2025-09-25T20:19:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-spectacle-lens-to-slow-myopia-progression-in-children 2025-09-25T20:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-rems-program-for-vandetanib-in-medullary-thyroid-cancer-after-decade-of-safe-use 2025-09-25T20:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-rems-program-for-vandetanib-in-medullary-thyroid-cancer-after-decade-of-safe-use 2025-09-25T20:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/clean-food-group-acquires-million-liter-fermentation-facility-to-scale-sustainable-oil-production 2025-09-25T20:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clean-food-group-acquires-million-liter-fermentation-facility-to-scale-sustainable-oil-production 2025-09-25T20:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/apiject-submits-first-of-kind-prefilled-plastic-injection-device-to-fda-for-approval 2025-09-25T20:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apiject-submits-first-of-kind-prefilled-plastic-injection-device-to-fda-for-approval 2025-09-25T20:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/qurient-and-synaffix-partner-to-develop-first-in-class-cdk7-dual-payload-adc-for-refractory-cancers 2025-09-25T20:18:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qurient-and-synaffix-partner-to-develop-first-in-class-cdk7-dual-payload-adc-for-refractory-cancers 2025-09-25T20:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-miami-enrolls-first-patients-in-pivotal-trial-testing-ai-powered-spine-pain-diagnostic-technology 2025-09-25T19:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-miami-enrolls-first-patients-in-pivotal-trial-testing-ai-powered-spine-pain-diagnostic-technology 2025-09-25T19:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-advances-ai-engineered-asthma-antibody-gb-0895-to-phase-3-trials-with-six-month-dosing-interval 2025-09-25T19:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generate-biomedicines-advances-ai-engineered-asthma-antibody-gb-0895-to-phase-3-trials-with-six-month-dosing-interval 2025-09-25T19:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-secures-japanese-patent-for-ampligen-combination-therapy-in-oncology-through-2039 2025-09-25T19:01:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-secures-japanese-patent-for-ampligen-combination-therapy-in-oncology-through-2039 2025-09-25T19:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/german-federal-patent-court-upholds-newron-s-xadago-patent-for-parkinson-s-disease-treatment 2025-09-25T19:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-federal-patent-court-upholds-newron-s-xadago-patent-for-parkinson-s-disease-treatment 2025-09-25T19:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-partners-with-miltenyi-biotec-to-advance-kir-car-platform-for-solid-tumor-treatment 2025-09-25T19:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-partners-with-miltenyi-biotec-to-advance-kir-car-platform-for-solid-tumor-treatment 2025-09-25T19:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-advances-polb-001-phase-2a-trial-to-prevent-cytokine-release-syndrome-in-multiple-myeloma 2025-09-25T19:00:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-advances-polb-001-phase-2a-trial-to-prevent-cytokine-release-syndrome-in-multiple-myeloma 2025-09-25T19:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-tau-targeting-immunotherapy-achieves-94-100-response-rate-in-alzheimer-s-phase-1b-2a-trial 2025-09-25T18:59:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-s-tau-targeting-immunotherapy-achieves-94-100-response-rate-in-alzheimer-s-phase-1b-2a-trial 2025-09-25T18:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-advances-commercial-ready-parkinson-s-cell-therapy-in-phase-1-2a-trial 2025-09-25T18:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-neuroscience-advances-commercial-ready-parkinson-s-cell-therapy-in-phase-1-2a-trial 2025-09-25T18:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-advances-bbt001-bispecific-antibody-to-patient-testing-following-promising-healthy-volunteer-data 2025-09-25T18:59:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-advances-bbt001-bispecific-antibody-to-patient-testing-following-promising-healthy-volunteer-data 2025-09-25T18:59:30+00:00 hourly 0.9 https://trial.medpath.com/news/clearnote-health-receives-uk-regulatory-approval-for-multi-cancer-detection-tests 2025-09-25T18:59:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearnote-health-receives-uk-regulatory-approval-for-multi-cancer-detection-tests 2025-09-25T18:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-trial-shows-promise-for-gut-microbiome-therapy-combined-with-immunotherapy-in-advanced-cancers 2025-09-25T18:58:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-2-trial-shows-promise-for-gut-microbiome-therapy-combined-with-immunotherapy-in-advanced-cancers 2025-09-25T18:58:49+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-15-6-million-to-advance-research-on-rare-bone-and-metabolic-disorders 2025-09-25T18:58:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-15-6-million-to-advance-research-on-rare-bone-and-metabolic-disorders 2025-09-25T18:58:43+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-out-licenses-ai-discovered-vaccine-candidate-evx-b3-to-merck-for-7-5m-upfront-592m-in-milestones 2025-09-25T18:57:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-out-licenses-ai-discovered-vaccine-candidate-evx-b3-to-merck-for-7-5m-upfront-592m-in-milestones 2025-09-25T18:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-advances-il-6-receptor-antibody-tzls-501-following-novartis-1-4b-tourmaline-acquisition 2025-09-25T18:57:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiziana-life-sciences-advances-il-6-receptor-antibody-tzls-501-following-novartis-1-4b-tourmaline-acquisition 2025-09-25T18:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-advances-ai-powered-parkinson-s-biomarker-discovery-program-for-strategic-pharma-partnerships 2025-09-25T18:56:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-advances-ai-powered-parkinson-s-biomarker-discovery-program-for-strategic-pharma-partnerships 2025-09-25T18:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/recode-precision-medicine-protocol-shows-dual-benefits-for-cognitive-decline-and-depression 2025-09-25T18:55:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-precision-medicine-protocol-shows-dual-benefits-for-cognitive-decline-and-depression 2025-09-25T18:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/quantoom-biosciences-partners-with-memorial-sloan-kettering-to-advance-personalized-rna-cancer-therapies 2025-09-25T18:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantoom-biosciences-partners-with-memorial-sloan-kettering-to-advance-personalized-rna-cancer-therapies 2025-09-25T18:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-launches-quantum-computing-initiative-to-revolutionize-3d-protein-modeling-for-drug-discovery 2025-09-25T18:55:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-launches-quantum-computing-initiative-to-revolutionize-3d-protein-modeling-for-drug-discovery 2025-09-25T18:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-third-orphan-drug-designation-to-biostar-s-utidelone-for-pancreatic-cancer-treatment 2025-09-25T18:54:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-third-orphan-drug-designation-to-biostar-s-utidelone-for-pancreatic-cancer-treatment 2025-09-25T18:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/axon-therapies-secures-32m-series-a-to-advance-novel-heart-failure-treatment-through-sympathetic-nervous-system-ablation 2025-09-25T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axon-therapies-secures-32m-series-a-to-advance-novel-heart-failure-treatment-through-sympathetic-nervous-system-ablation 2025-09-25T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-secures-95-million-series-b-to-advance-novel-diabetes-treatment-targeting-elevated-cortisol 2025-09-25T13:16:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparrow-pharmaceuticals-secures-95-million-series-b-to-advance-novel-diabetes-treatment-targeting-elevated-cortisol 2025-09-25T13:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-to-present-final-defiance-phase-2-results-for-sirexatamab-in-advanced-colorectal-cancer-at-esmo-2025 2025-09-25T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-to-present-final-defiance-phase-2-results-for-sirexatamab-in-advanced-colorectal-cancer-at-esmo-2025 2025-09-25T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-advances-two-drug-development-programs-with-cdsco-regulatory-approvals 2025-09-25T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-advances-two-drug-development-programs-with-cdsco-regulatory-approvals 2025-09-25T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-new-safety-signals-for-sonidegib-in-basal-cell-carcinoma-treatment 2025-09-25T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-analysis-reveals-new-safety-signals-for-sonidegib-in-basal-cell-carcinoma-treatment 2025-09-25T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-presents-breakthrough-cancer-data-at-esmo-2025-showcasing-unprecedented-survival-results 2025-09-25T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-presents-breakthrough-cancer-data-at-esmo-2025-showcasing-unprecedented-survival-results 2025-09-25T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-qulipta-gains-public-reimbursement-in-quebec-for-migraine-prevention 2025-09-25T13:14:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-qulipta-gains-public-reimbursement-in-quebec-for-migraine-prevention 2025-09-25T13:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/levicept-s-levi-04-shows-dual-benefit-in-osteoarthritis-reduces-bone-marrow-lesions-while-alleviating-pain 2025-09-25T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/levicept-s-levi-04-shows-dual-benefit-in-osteoarthritis-reduces-bone-marrow-lesions-while-alleviating-pain 2025-09-25T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/pi-health-partners-with-gsk-to-accelerate-phase-2-oncology-trial-using-ai-powered-platform 2025-09-25T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pi-health-partners-with-gsk-to-accelerate-phase-2-oncology-trial-using-ai-powered-platform 2025-09-25T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-three-draft-guidances-to-accelerate-cell-and-gene-therapy-development-through-innovative-trial-designs 2025-09-25T13:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-three-draft-guidances-to-accelerate-cell-and-gene-therapy-development-through-innovative-trial-designs 2025-09-25T13:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/marine-sponge-compounds-show-promise-as-novel-leishmaniasis-treatments 2025-09-25T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marine-sponge-compounds-show-promise-as-novel-leishmaniasis-treatments 2025-09-25T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-advances-us-commercialization-of-alfapump-system-with-cms-reimbursement-approval 2025-09-25T09:16:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequana-medical-advances-us-commercialization-of-alfapump-system-with-cms-reimbursement-approval 2025-09-25T09:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-develops-novel-mrna-vaginal-gel-therapy-for-heavy-menstrual-bleeding 2025-09-25T09:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-medicine-develops-novel-mrna-vaginal-gel-therapy-for-heavy-menstrual-bleeding 2025-09-25T09:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/huntington-s-disease-pipeline-shows-strong-growth-with-over-20-companies-developing-novel-therapies 2025-09-25T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huntington-s-disease-pipeline-shows-strong-growth-with-over-20-companies-developing-novel-therapies 2025-09-25T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/monash-university-researchers-develop-entelli-02-phage-cocktail-to-combat-antimicrobial-resistant-enterobacter-infections 2025-09-25T09:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monash-university-researchers-develop-entelli-02-phage-cocktail-to-combat-antimicrobial-resistant-enterobacter-infections 2025-09-25T09:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/essa-pharma-amends-xenotherapeutics-agreement-reduces-shareholder-payout-to-0-12-per-share 2025-09-25T09:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essa-pharma-amends-xenotherapeutics-agreement-reduces-shareholder-payout-to-0-12-per-share 2025-09-25T09:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/advocate-health-launches-nation-s-largest-clinical-trial-network-with-69-hospitals-and-six-million-patients 2025-09-25T09:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advocate-health-launches-nation-s-largest-clinical-trial-network-with-69-hospitals-and-six-million-patients 2025-09-25T09:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/global-medical-research-funders-unite-to-strengthen-clinical-trial-standards-worldwide 2025-09-25T09:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-medical-research-funders-unite-to-strengthen-clinical-trial-standards-worldwide 2025-09-25T09:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-partners-with-evestia-clinical-for-phase-1b-trial-of-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-09-25T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-partners-with-evestia-clinical-for-phase-1b-trial-of-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-09-25T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-car-t-cell-expansion-linked-to-delayed-neurotoxicity-risk-in-multiple-myeloma-patients-receiving-cilta-cel 2025-09-25T05:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-car-t-cell-expansion-linked-to-delayed-neurotoxicity-risk-in-multiple-myeloma-patients-receiving-cilta-cel 2025-09-25T05:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/st-louis-children-s-hospital-begins-administering-fda-approved-gene-therapy-lyfgenia-for-sickle-cell-disease 2025-09-25T05:16:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-louis-children-s-hospital-begins-administering-fda-approved-gene-therapy-lyfgenia-for-sickle-cell-disease 2025-09-25T05:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/manas-ai-secures-26-million-seed-extension-to-advance-ai-driven-drug-discovery-platform 2025-09-25T05:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manas-ai-secures-26-million-seed-extension-to-advance-ai-driven-drug-discovery-platform 2025-09-25T05:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/startnewera-phase-ii-trial-shows-promising-5-year-outcomes-for-stereotactic-radiotherapy-in-advanced-lung-cancer 2025-09-25T05:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/startnewera-phase-ii-trial-shows-promising-5-year-outcomes-for-stereotactic-radiotherapy-in-advanced-lung-cancer 2025-09-25T05:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-initiates-phase-3-trial-for-novel-diabetic-foot-infection-treatment-in-indonesia 2025-09-25T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-initiates-phase-3-trial-for-novel-diabetic-foot-infection-treatment-in-indonesia 2025-09-25T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/hetlioz-demonstrates-significant-sleep-improvement-in-primary-insomnia-trial-published-in-plos-one 2025-09-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hetlioz-demonstrates-significant-sleep-improvement-in-primary-insomnia-trial-published-in-plos-one 2025-09-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-year-study-reveals-hidden-pre-clinical-stage-of-rheumatoid-arthritis 2025-09-25T01:28:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-year-study-reveals-hidden-pre-clinical-stage-of-rheumatoid-arthritis 2025-09-25T01:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-and-ge-healthcare-partner-to-bring-psma-pet-imaging-agent-pylarify-to-japan-s-prostate-cancer-market 2025-09-25T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-and-ge-healthcare-partner-to-bring-psma-pet-imaging-agent-pylarify-to-japan-s-prostate-cancer-market 2025-09-25T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-opens-first-uk-mrna-manufacturing-facility-in-oxfordshire-strengthening-pandemic-preparedness 2025-09-25T01:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-opens-first-uk-mrna-manufacturing-facility-in-oxfordshire-strengthening-pandemic-preparedness 2025-09-25T01:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-and-jamp-pharma-launch-neutropenia-biosimilars-in-canada 2025-09-25T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kashiv-biosciences-and-jamp-pharma-launch-neutropenia-biosimilars-in-canada 2025-09-25T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/faeth-therapeutics-reports-positive-phase-2-results-for-sapanisertib-in-ovarian-cancer-treatment 2025-09-25T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faeth-therapeutics-reports-positive-phase-2-results-for-sapanisertib-in-ovarian-cancer-treatment 2025-09-25T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-identify-stk17b-kinase-as-key-target-for-overcoming-multiple-myeloma-drug-resistance 2025-09-25T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-researchers-identify-stk17b-kinase-as-key-target-for-overcoming-multiple-myeloma-drug-resistance 2025-09-25T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-heparin-reduces-covid-19-ventilation-risk-by-50-in-international-trial 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhaled-heparin-reduces-covid-19-ventilation-risk-by-50-in-international-trial 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-park-cdmo-partners-with-thermo-fisher-to-expand-viral-vector-manufacturing-capacity-in-south-korea 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-park-cdmo-partners-with-thermo-fisher-to-expand-viral-vector-manufacturing-capacity-in-south-korea 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/camkk2-enzyme-knockout-in-immune-cells-prevents-diet-induced-obesity-and-diabetes-in-mice 2025-09-24T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camkk2-enzyme-knockout-in-immune-cells-prevents-diet-induced-obesity-and-diabetes-in-mice 2025-09-24T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-zyn002-phase-3-trial-fails-to-meet-primary-endpoint-in-fragile-x-syndrome 2025-09-24T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-zyn002-phase-3-trial-fails-to-meet-primary-endpoint-in-fragile-x-syndrome 2025-09-24T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/quantumzyme-secures-uspto-patent-for-green-enzymatic-ibuprofen-manufacturing-process 2025-09-24T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantumzyme-secures-uspto-patent-for-green-enzymatic-ibuprofen-manufacturing-process 2025-09-24T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-bioscience-s-self-replicating-rna-rabies-vaccine-shows-superior-durability-in-phase-i-trial 2025-09-24T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replicate-bioscience-s-self-replicating-rna-rabies-vaccine-shows-superior-durability-in-phase-i-trial 2025-09-24T17:20:38+00:00 hourly 0.9